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CHARACTERIZATION OF CUCURBITACIN -INSPIRED ESTRONE ANALOGUES 
AS NOVEL INHIBITORS OF HUMAN ATP-BINDING CASSETTE PROTEINS  
(ABCB1 AND ABCC1) 
JENNIFER KYEREMATENG  
2021 
ATP-binding cassette (ABC) transporters are a large class of integral membrane 
proteins that contribute to key physiological functions in all organisms by 
utilizing ATP binding and hydrolysis to transport diverse substrates across 
membrane barriers. P-glycoprotein (P-gp/ ABCB1) and Multidrug Resistance 
protein 1 (MRP1/ABCC1) are widely reported ABC transporters associated with 
multidrug resistance in cancer. Multidrug resistance (MDR) mediated by P-gp and 
MRP1 is responsible for treatment failures of many metastatic cancers as a result 
of reduced accumulation, bioavailability and diminished potency of anticancer 
drugs. Currently, known P-gp and MRP1 inhibitors are limited due to toxicity, 
lack of selectivity and low therapeutic benefit which necessitates the investigation 
of novel compounds with improved potency and specificity. In this study, we 
investigated the inhibition potential of newly synthesized cucurbitacin-inspired 
estrone analogs (CIEAs) on P-gp and MRP1 mediated MDR. Utilizing a high 
content fluorescence-based transport activity assay initially developed in our lab, 
a library of 81 CIEAs were screened to identify inhibitors for P-gp and MRP1 
xiv 
 
proteins. The screening assay identified eight P-gp inhibitors using calcein-AM as 
a fluorescent reporter. A total of six MRP1 inhibitors were identified using 
doxorubicin and calcein red orange as fluorescent reporters. The inhibitory effect 
of the identified compounds on P-gp and MRP1 activity were confirmed using 
established cell-based functional assays. The identified inhibitors significantly 
increased the accumulation of P-gp substrate, calcein-AM and MRP1 substrates, 
doxorubicin and calcein red orange.  Interestingly, the identified inhibitors 
demonstrated selective sensitization of P-gp and MRP1 overexpressing cancer 
cell lines towards different anticancer drugs. On the other hand, the identified 
inhibitors did not alter protein levels of both P-gp and MRP1. Furthermore, our in 
silico and FRET-based spectroscopic studies showed that the inhibitor compounds 
directly interact with P-gp and MRP1 proteins. Together, our findings 
demonstrated that CIEAs are promising drug candidates for further development 








Introduction and Background 
 
1.1 Cell Transport and Membrane Transport Proteins 
 
Cell transport is the movement of molecules across biological membranes. 
Biological membranes serve as the boundary that separates the cell and other intracellular 
organelles from their external environment. These membranes are essential for 
intracellular transport by controlling the selective movement of molecules in and out of 
cells. Generally, transport of molecules is mediated by specific membrane-associated 
proteins, though some transport processes are unassisted by proteins. These membrane-
associated proteins are called membrane transport proteins. Membrane transport proteins 
play a critical role in regulating several biochemical pathways. Notably, they regulate the 
entry of essential substances such as nutrients and ions necessary for metabolism into 
organelles thus maintaining cellular homeostasis while also driving the removal of 
endogenous waste, toxic substances, metabolites and drugs out of the cell. Consistent 
with their crucial role, transporters or transporter related proteins are encoded by 
approximately 2000 genes in the human genome [1]. In addition, their importance may be 
appreciated from the fact that cells that have defective transport systems have been linked 
to several pathological conditions such as metabolic disorders [2, 3] and cancer [4]. Also, 
it is not surprising that membrane transporters constitute over 50% of all known drug 
targets [5]. Therefore, an extensive knowledge in membrane transport proteins is central 
to understanding cell metabolism and function. Membrane transport proteins or 




aquaporins; ion channels; transporters; and ATP-powered pumps [6]. Aquaporins are 
water channel proteins that utilize osmotic gradients across membranes to transport 
uncharged molecules (water) into and out of cells [7].  Ion channels on the other hand, are 
the cell’s electric potential regulator proteins that facilitate the transport of charged 
species or ions down their electrochemical gradient across the plasma membrane. While 
transporters drive the movement of specific molecules along or against their 
concentration gradients by undergoing conformational changes, ATP-powered pumps 
transport molecules against their concentration gradients across the plasma membrane 
using energy derived from ATP hydrolysis [6]. Membrane transporters can also be 
classified as passive or active based on their reliability on cellular energy [6]. Passive 
transporters also known as uniporters or facilitative transporters, mediate the energy-
independent transport of substrates across the plasma membrane down their concentration 
gradient with the aid of special carrier proteins. Active transporters instead, translocate 
substrates against or down their concentration gradient in an energy-dependent manner. 
However, active transporters that directly depend on energy derived from ATP hydrolysis 
to mediate transport are known as primary active transporters. Secondary active 
transporters indirectly utilize energy from coupling reactions of the transported molecule 
with another molecule along their concentration gradient sometimes driven by H+ ions 
(proton) or sodium motive forces. The transporter is termed as symporter when the 
transported and co-transported molecules are moved in the same direction or antiporter 
when both molecules are transported in opposite directions. A diagrammatic presentation 




ATP-binding cassette (ABC) transporters, the transporters of interest in this study are 
examples of ATP-powered pumps or transport ATPases that include F-, V- and P-type 
ATPases and also fall under primary active transporters [8]. An overview of the ATP 
transporter family is discussed in the next sections. 
 
 
Figure 1.1 Membrane transport processes. Diagrammatic representation of the various 
mechanisms for the passage/transport of ions and molecules across biological membranes 
[9]. 
 
1.2 The ABC Transporter Family 
 
ABC transporters constitute a large family of integral transmembrane proteins that 
contribute to key physiological processes in all organisms. They are involved in 
transporting diverse substrates across membrane barriers using energy derived from ATP 
hydrolysis. Substrates of ABC transporters may include small molecules such as ions, 
amino acids, polysaccharides, vitamins, lipids, antibiotics, and drugs to even large 




as cell growth and development, nutrients translocation, cellular detoxification, lipid 
homeostasis, signal transduction and cellular defense [11].  
The fundamental protein architecture of a typical ABC transporter consists of two 
nucleotide binding domains (NBDs) and two transmembrane domains (TMDs) [12]. The 
TMDs are also called membrane spanning domains (MSD) in some literature. The NBDs, 
also known as ATP-binding cassette (ABC) from which this family of transporters derive 
their name are highly conserved and serve as the motor for energy generation from ATP 
binding and hydrolysis. Unlike the NBDs, TMDs are more diverse, and responsible for 
substrate recognition and translocation [12].  During transport, substrates may be 
recruited either from the inner leaflet  (cis-side) or the outer leaflet (trans-side) of the cell 
membrane. Subsequently, there is ATP binding and hydrolysis at the cytoplasmic side of 
the membrane which then initiates the opening and closing of the TMDs for possible 
substrate transport [13]. Based on this cis or trans direction of transport, a given ABC 
transporter may function as an importer or exporter. Importers direct substrates from the 
trans-side to the cis-side of the membrane. In contrast, ABC exporters translocate 
substrates from the cytoplasm to the trans-side, or from the hydrophobic portion of the 
lipid bilayer to the trans-side or across the inner and outer parts of the bilayer [13, 14]. In 
general, exporters are found in all kingdoms while importers are limited to bacteria and 
plants [15, 16]. In bacteria, ABC importers mediate the influx of essential nutrients while 
exporters typically efflux drug substrates across the membrane [17]. An interesting 
bacterial ABC exporter is LmrA, found in Lactobacillus lactis. LmrA was the first ABC-




Importers and exporters also differ by the structural organization of their NBD 
and TMD domains. The NBD and TMDs in exporters can be combined in various ways 
creating a full transporter with varying order of domains. However, for importers, the 
TMD and NBD domains are distinct chains and can associate to form a homo- or hetero-
dimeric domains to create a half transporter [14, 17]. Despite these differences, it is 
suggested that both transporter types bind ATP and substrates in a similar fashion. In 
effect, exporters and importers utilize the same ATP binding and hydrolysis mechanism 
to alternate between inward-facing and outward-facing conformations of the transporter 
[19, 20]. However, for bacteria importers, substrate translocation requires a high affinity 
substrate binding protein (SBP) for delivery to the TMDs [21]. With ongoing studies on 
characterization of ABC transporters, more sub-classifications based on structural and 
functional diversity have been identified [13, 14, 17]. For instance the Type I and II sub-
groups have been reported for both ABC exporters and importers. A more recent group, 
the Energy-Coupling Factor transporters (ECF) or Type III ABC importers have also 
been reported to play specific functions in prokaryotes [22, 23].  
 
1.3 Human ABC Transporter Genes and Associated Diseases 
 
The mammalian species have a total of 56 ABC transporter genes of which 48 
genes have been identified in the human genome [10]. The 48 human ABC transporter 
genes can be grouped into seven unique subfamilies designated ABCA - ABCG 
according to their domain organization and sequence homology. Human ABC 
transporters are well known to play pivotal roles in many cellular processes such that 




transporter genes are related to various genetic disorders. A brief description of the 
subfamilies and their associated genetic diseases are discussed in this section. 
The ABCA subfamily consists of twelve full transporters and are subdivided into 
two groups based on phylogenetic relationships [24]. They are mainly responsible for 
lipid transport and homeostasis, regulation of membrane trafficking [25] and retinal 
transport [26]. Mutations in the ABCA1 transporter gene results in Tangier disease, a 
disorder associated with lipoprotein metabolism [27]; Sjögren syndrome, an autoimmune 
disease is due to defects in ABCA7 gene [28] while defects in ABCA4 genes have been 
associated with retinal diseases [29].  
The ABCB transporters are the only subfamily made up of both half and full 
transporters [30]. They are involved in mitochondrial transport, oxidative stress defense 
[31], intracellular peptide translocation, antigen processing , DNA repair and 
chromosome recombination [32]. Defects in some of these transporter genes (ABCB4 
and ABCB11) have been linked to a group of liver diseases known as progressive 
familial intrahepatic cholestasis (PFIC) [33]. They are also remarkable for their affinity to 
multiple substrates including drugs. The most prominent of this class is 
ABCB1(Permeability-glycoprotein) which plays a significant role in multidrug resistance 
associated with many tumor cells.  
The ABCC subfamily constitute 12 full transporters which are commonly drug 
transporters and multidrug resistance proteins (MRPs). This group also contains ‘non 
typical’ ABC transporters like the cystic fibrosis transmembrane regulator 
(CFTR/ABCC7) which is particularly a cAMP-regulated chloride ion channel [34] and 




transport, the ABCC transporters are also engaged in lipid transport [37], nucleotide and 
nucleoside analog transport [38]; glutathione and anion conjugate transport [30]; signal 
transduction and chemotaxis; inflammatory responses; cell migration and detoxification 
[39]. Some of the known genetic disorders associated with this subfamily are cystic 
fibrosis (CF) and Dubin-Johnson syndrome. CF is an autosomal recessive disorder caused 
by mutations in CFTR/ABCC7 gene which results in the malfunction of various body 
systems such as the respiratory, digestive and endocrine systems [40]. Although several 
CFTR gene mutations have been identified, deletion of three bases coding for 
phenylalanine at position 508 (F508del)  is the most common mutation associated with 
CF [40]. The mutation leads to protein misfolding with defective protein trafficking and 
post translational modifications. Dubin-Johnson syndrome results from mutations in 
ABCC2/MRP2 or canalicular multispecific organic anion transporter (cMOAT) gene. 
Such mutations include deletions of Arg1392 and Met1393, causing abnormalities in 
protein maturation and trafficking [41]. ABCC2 is an organic anion transporter localized 
mostly to canalicular membranes of hepatocytes where it is actively involved in biliary 
transport of endogenous and exogenous compounds hence the disease is characterized by 
a bile-associated liver disorder [41][42]. Defects in ABCC6 genes have also been 
reported to cause pseudoxanthoma elasticum (PXE), a connective tissue disorder [43]. 
Consistent with their drug transport function, members of this subfamily (ABCC1, 
ABCC2, ABCC3, ABCC4, ABCC6, ABCC10 and ABCC11) are multidrug resistance 
proteins and are highly expressed in a variety of cancers where they contribute to 
chemoresistance and disease progression [44]. The most well studied among this group is 




The ABCD subfamily genes consist of four half transporters mainly involved in 
peroxisomal transport of very long chain fatty acids (VLCFA) [45]. An exception to this 
function is the ABCD4 transporter, which is localized in lysosomes and endoplasmic 
reticulum (ER) and involved in intracellular transport of Vitamin B12 [46]. The effects of 
ABCD gene mutations are peroxisomal disorders such as X-linked adrenoleukodystrophy 
(ABCD1), which is caused by toxic concentrations of VLCFA. Mutations in ABCD3 
have also been linked to spleen disorders (hepatosplenomegaly) while defects in ABCD4 
gene are associated with abnormal Vitamin B12 metabolic disorders [46, 47]. The ABCE 
and ABCF subfamilies though called ABC transporters, do not act as transporters due to 
the absence of TMD in their structure. They are rather thought to play significant roles in 
cell division and regulation of translation initiation factors [48-50]. 
The last group of the ABC transporters, the ABCG subfamily members are lipid 
and cholesterol transporters. Mutations in their genes are associated with toxic 
intracellular amounts of cholesterol in liver and intestines [51]. ABCG2 or breast cancer 
resistant protein (BCRP) is the most-studied member of this subfamily and function as a 
drug efflux pump that confers drug resistance in many cancer cells. It is also known to 
play a vital role in renal uric acid transport. Therefore mutations in ABCG2 gene result in 



















Figure 1.2 Phylogenetic tree showing human ABC transporter gene family. The root 
‘ABC’ is omitted from the figure to simplify it. Thus, the correct gene name for ‘B1’ is 
ABCB1, for ‘B4’ is ABCB4, and so forth [6].  
 
1.3 Structure, Organization and Mechanistic function of ABC Transporters 
 
A typical eukaryotic ABC transporter consists of a single polypeptide organized into 
four functional units or domains that can be found associated in the membrane. The 




transmembrane domains (TMDs) make up the fundamental architecture of the 
transporter. The NBDs belong to a group of nucleotide binding proteins (NTP) known as 
P-loop NTPases that require the catalytic activity of magnesium ions to function [53]. 
The NBDs are also hydrophilic in nature and located at the cytoplasmic side of the 
membrane [54]. Each NBD contains two subdomains (Figure 1.3B): a catalytic or RecA-












Figure 1.3 Schematic representation of NBDs and coupling helices. (A) Side view (from 
the membrane plane) of an ABC transporter. NBDs (blue and green) are attached to the 
TMDs (gray) via so-called coupling helices (red) present in loops of the TMDs. ATP 
binding and hydrolysis cause rearrangements in the NBDs, which are propagated to the 




membrane) of the NBDs and the coupling helices from the TMDs. (C) The relative 
positions of sequence motifs in NBDs [13] 
 
The domains are evolutionary highly conserved with various sequence motifs performing 
specific functions for ATP catalysis during substrate transport [13, 14, 54, 55]. The 
RecA-like domain starts from the N-terminal with the A-loop motif (Figure 1.3C). The 
A-loop has a conserved aromatic residue (mainly tyrosine) responsible for assembling the 
adenine ring of ATP for better anchorage during ATP binding. Next, the Walker A (P-
loop) motif (GXXGXGK(S/T)) which contains highly conserved lysine residues is the 
part of the NBD that interacts with the phosphate groups of ATP. The Q-loop follows the 
Walker A motif. This has highly conserved glutamine residues and serves as the active 
site for ATP hydrolysis and the main point of connection with the TMDs. The C or ABC 
motif begins the helical domain. The consensus sequence of this motif (LSGGQ) is the 
signature feature of all ABC transporters and it functions to position the helix for 
interaction with the phosphate groups of ATP. The Walker B (φφφφDE, φ = hydrophobic 
residue) motif with its conserved glutamate residue acts as a polarizing base for ATP 
against attack by water molecules. The D-loop motif (SALD) comes next to the Walker B 
and helps to create the platform for ATP hydrolysis. The H-loop or H-switch ends the 
NBD at the C terminus. It has a highly conserved histidine residue responsible for 
essential interaction with other motifs at the catalytic site. 
Unlike the NBDs, the TMDs are highly hydrophobic and depending on the 
transporter subfamily, each TMD may contain 6-11 (usually 6 for eukaryotic ABC 




transporter, the TMD may contain a total of 12 transmembrane spanning α-helix 
segments. Largely, the TMDs show no substantial sequence similarity and are thus 
structurally heterogenous though they may share similar network within the same 
transporter subfamily.  The structural dissimilarity thereof for TMDs is suggested to be 
responsible for the broad specificity of ABC transporters to a variety of substrates. This is 
especially evident for the multidrug transporter P-glycoprotein (P-gp) which has been 
termed to exhibit ‘polyspecificity’ to a number of substrates [57].  In addition, 
experiments done on human P-gp and multidrug exporter Sav1866 from Staphylococcus 
aureus revealed that the TMD helical segments are arranged in a manner that creates a 
substrate translocation pathway extending from the cytoplasm towards the membrane 
exterior [14, 58].  
Under normal cell function, ABC transporters transverse substrates across the 
membrane against a concentration gradient using energy derived from ATP binding and 
hydrolysis. For exporters, this transport process is done in a unidirectional manner. This 
means that the transporter functional domains must operate in a complementary manner 
for the transport to occur. The transduction of conformational changes between the NBDs 
and TMDs is said to be crucial for this mechanistic transport process. Despite the NBD-
TMD dissimilarities, their domain interactions are made possible through coupling 
helices identified in the TMDs [19]. The coupling helix describes a brief α-helical motif 
present at one of the cytoplasmic projections of the TMD that fits into a pocket of a NDB. 
The coupling interaction between the TMDs and NBDs in this manner is necessary for 
transmitting conformational changes from the catalytic site of the NBDs to the TMDs. 




helical and RecA-like subdomains where the Q-loop motif is located. The interface of the 
two subdomains plus the conserved glutamine in the Q-loop motif facilitates this 
interaction. Moreover, crystallography studies on some ABC transporters also suggest 
that the dimerization of NBDs in a ‘sandwich’ fashion is central to the conformational 
changes in TMDs [59].  Consequently, more studies have proposed several mechanistic 
transport models such as the ATP- switch [60], alternating catalytic site [61], constant 
contact [62] and the reciprocating twin-channel [63].  
The ATP- switch model proposed by Higgins and Linton is the most commonly 
cited mechanistic model for ABC proteins [60]. This model describes the switching of 
two conformations of the NBDs alongside ATP binding and hydrolysis and the resulting 
conformational changes induction in the TMDs. With respect to substrate translocation in 
ABC exporters, the transport cycle is triggered by binding of the substrate to the TMDs. 
The presumable binding of substrate to the high-affinity TMDs site promotes the 
transformation of the open NBD dimer (low ATP affinity) conformation to the closed 
dimer (high ATP affinity) conformation. In essence, the binding of substrate favors the 
closed dimer conformation by lowering the activation energy of the process and also 
increasing the NBDs affinity for ATP. Binding of two ATP molecules at the interface of 
the NBDs and the closed dimer formation induce non-covalent conformational changes in 
the TMDs. The changes in the conformation of the TMDs reduce the binding affinity of 
the substrate allowing it to be released. ATP is subsequently hydrolyzed with release of 
ADP, and inorganic phosphate. The NBDs are dissociated and finally reset to their 




substrate-induced conformational changes consistent with the ATP-switch model have 
been reported in transport studies for P-gp [64, 65] and MRP 1 [66]. 
 
1.5 Human ABC Transporters and Multidrug Resistance in Cancer 
 
The World Health Organization (WHO; www.who.int) reports cancer as the 
second leading cause of mortality worldwide after heart disease, accounting for ~ 9.6 
million deaths or 1 in every 6 deaths in 2018. The number of new cancer cases reported 
in 2018 was ~ 18.1 million and by 2030, this number is expected to increase by more 
than 80% annually [67]. Current cancer treatment modalities include chemotherapy, 
radiotherapy, immunotherapy and surgery though chemotherapy remains the traditional 
approach for managing cancer [68]. Notwithstanding the substantial progress made in 
chemotherapy, survival rates in many cancer types still remain significantly low 
unfortunately due to multidrug resistance (MDR) mechanisms. MDR is believed to be 
responsible for treatment failure in more than 90% of patients with metastatic cancers 
[69].  The multidrug resistance term describes the ability of cancer cells to develop cross 
resistance to a number of structurally and pharmacologically unrelated chemotherapeutic 
agents [70] . The underlying mechanisms (Figure 1.4) identified to cause MDR include 
increased drug efflux, reduced drug influx, drug target alteration, deactivation of drug 
metabolic and apoptotic mechanisms as well as mutations among others. The most 
frequent and the widely studied mechanism is increased drug efflux mediated by ABC 
transporters [71]. Amongst the ABC efflux pumps identified as drug transporters, P-




MDR related cancers. This work focuses on multidrug resistance mediated by P-
























1.6 Permeability Glycoprotein (P-gp/ABCB1) 
 
P-gp is the first to be discovered in the human ABC transporter family and the 
most extensively characterized ABC protein. P-gp protein was originally identified 
overexpressed in tumor cells of Chinese hamster selected for multidrug resistance and 
was later cloned in mouse and humans [73]. The fundamental core of P-gp consists of 
two NBDs and two TMDs as shown in Figure 1.5. The NBD and TMD domains 
organization for substrate translocation using energy derived from ATP binding and 
hydrolysis depicted by P-gp is characteristically the same for the family of ABC efflux 
transporters. The P-gp gene (mdr1) is encoded with 1280 amino acids giving a 170 kDa 
protein separated into two homologous halves located at the N- and C- terminals [74, 75]. 
Each homologous half contains a NBD accompanied by a TMD with six transmembrane 
spanning helices. A flexible linker peptide or region of approximately 75 amino acids 
connects the two halves. The linker region is responsible for proper interaction of the two 
halves and also couple ATPase activity for drug binding and efficient P-gp transport 
function [74, 75].  
 
 




The diversity of substrates transported by P-gp may include neutral or positively 
charged compounds but mainly amphipathic or hydrophobic compounds that can 
appreciably penetrate the plasma membrane into tissues [77]. Many of the substrates 
include various anticancer drugs such as vinca alkaloids, anthracyclines, 
epipodophyllotoxins and clinically important therapeutics like HIV protease inhibitors, 
cardiac glycosides, immunosuppressive agents, antibiotics and corticoids [77]. 
Considering the unique ability of P-gp to transport a variety of chemically diverse 
compounds, the molecular basis behind its broad substrate and polyspecificity is still not 
clear. Nonetheless, critical studies of P-gp structure, the nature of its TMDs and the drug 
binding sites have shed light onto its unique properties. High-resolution crystal structures 
of mouse P-gp (87% sequence similarity to human P-gp) by Aller et al revealed that P-gp 
can differentiate between stereoisomeric compounds and consequently generate distinct 
binding spots with varied orientational chemistries for multiple substrates [57]. 
Furthermore, an inward facing conformation of the TMDs facilitates the formation of an 
internal cavity (of volume ∼6,000 Å3 ) which is large enough to hold at least two 
different substrates concurrently [78]. Additionally, the TMDs conformations promote 
different topologies of the drug binding pocket which is characterized by highly 
conserved residues [79]. The flexibility of the drug binding pocket topologies in addition 
to the highly conserved residues in the pocket may account for the substrate 
polyspecificity nature of P-gp. The ability of P-gp to transport diverse molecules 
especially hydrophobic substrates can be explained by the abundance of hydrophobic and 
aromatic residues in the drug binding pocket that permit the recruitment and partitioning 




activity, P-gp is able to identify substrates from the bilayer or inner leaflet of the 
membrane and ‘flip’ or extrude them into the outer leaflet of the membrane or 
extracellular environment. Mutational and photolabeling experiments of P-gp have also 
confirmed the contribution of the TMDs to substrate specificity [74, 80]. In short, the 
TMDs, the large internal cavity, the drug binding pockets and conformational changes 
allow P-gp to scan, accommodate and bind diverse substrates and subsequently extrude 
them out of the cell.  
 
The distribution of P-gp in normal physiology is important for major cellular 
functions like lipid homeostasis, metabolite excretion, among others. P-gp is localized to 
apical membranes of specialized epithelial cells of the intestines, kidney, liver and 
pancreas where major metabolites excretion occur [81]. P-gp is also expressed in 
endothelial cells of luminal blood barriers of sensitive tissues such as the brain, nerves, 
testis and the placenta and thus plays an important physiological role in tissue defense 
against xenobiotics [82]. Consistent to the essential role played by P-gp in sensitive 
tissues, the pathological effects of cytotoxic drugs in the brain, testes and placenta have 
been demonstrated in numerous experimental models. An important example is the 
increase in fetal sensitivity to teratogenic substrates among other cytotoxins and 
subsequent neonatal abnormalities often reported in the placenta of P-gp knockout mice 
[83, 84]. On the other hand, overexpression of P-gp in brain and nerve tissues in diseased 
conditions may impede pharmacological behavior of selective therapeutics such as 





Given its crucial physiological functions in normal cells, P-gp overexpression in 
tumor cells is a crucial index for drug pharmacokinetics such as the absorption, 
distribution, metabolism and excretion (ADME) of orally administered chemotherapeutic 
drugs. Reduced intracellular drug bioavailability is a major obstacle to successful 
chemotherapy. Although not always the case, a viable correlation between elevated levels 
of P-gp, tumor insensitivity and patient response or survival rates have been established 
in some hematological malignancies (leukemias), neuroblastoma, colon, adrenal, bladder, 
breast and endometrial carcinomas [86-89]. 
 
1.7 Multidrug Resistance Protein 1 (MRP1/ABCC1) 
 
Multidrug resistance protein 1 (MRP1) is the second known ABC transporter 
implicated in clinical multidrug resistance. MRP1 was initially identified for its role in 
conferring resistance to a number of anticancer drugs in a doxorubicin-selected lung 
cancer cell line (NCI-H69) which was not overexpressing P-gp [90]. The 190 kDa MRP1 
(encoded with 1531 amino acids) has an extra membrane spanning domain (MSD0) 
(Figure 1.6) with five transmembrane helices at the N-terminal region in addition to the 
typical four core domains (two NBDs and two MSDs) observed in P-gp and other ABC 
proteins [91]. The twelve transmembrane helices in the MSD1 and MSD2  (as shown in 
Figure 1.6) form the substrate translocation pore through which solutes are transported, 
however, the function of the MSD0 in relation to MRP1 transport activity is not well 
understood [92]. MRP1 transport is governed by ATP binding and hydrolysis with 
conformational change transduction from the NBDs to the MSDs. Transport is initiated 




head-to-tail orientation and sandwich dimer formation of the NBDs. ATP-binding and 
dimerization of the NBDs are facilitated by three characteristic sequence motifs in the 
NBDs: the Walker A, Walker B and the signature C motifs [63, 92] . Interestingly, ATP 
binding to the NBDs is asymmetrical, generating two sites namely: the ‘degenerate’ and 
‘consensus’ sites [63, 93]. Whereas the NBD1 has a low ATPase activity with higher 
affinity for ATP binding at the degenerate site, the NBD2 on the other hand, has a higher 
ATP hydrolysis ability at the consensus site [93]. The asymmetric catalytic activity at the 
NBDs is a characteristic feature of MRP1 and the other members of its subfamily but not 




Figure 1.6 Topology and domain structure of MRP1 [94]. 
 
The substrates of MRP1 are mostly organic anions from endogenous or 
exogenous sources  several of which are conjugated to glutathione, glucuronic acid or 




remarkably amphipathic and thus contain predominantly polar amino acids. Conversely, 
corresponding TMs (5, 6, 11 and 12) of P-gp are less amphipathic accounting for the 
ability of P-gp to transport mostly hydrophobic substrates but not hydrophilic organic 
anionic compounds [92]. Furthermore, the TMDs in MRP1 have comparably large 
number of ionizable amino acids. Evidence suggests that the TMDs residues have 
hydrogen-bonding abilities that favor intrahelical or interhelical ion pair interactions with 
hydrophilic organic anions [96]. MRP1 also transports a broad range of antineoplastic 
agents such as vinca alkaloids, epipodophyllotoxins, methotrexate and camptothecins 
many of which are also substrates of P-gp. Many clinically important therapeutics e.g. 
antibiotics, antivirals, antidepressants, statins and metal oxyanions are also substrates of 
MRP1 [94, 97]. Additionally, MRP1 is the primary transporter of endogenous anionic 
substrates such as glutathione (GSH), cobalamin, bilirubin, estradiol glucuronide 
(E217βG) and cysteinyl leukotriene (LTC4) [98-100]. The ATP-dependent transport of 
the antioxidant GSH and the pro-inflammatory molecule LTC4, presents MRP1 as an 
essential mediator in cellular redox homeostasis, cell differentiation, proliferation and 
immunological reactions. Therefore, it is not surprising that MRP1is associated with the 
etiology of many metabolic, cardiovascular, neurological, immunological and tumor 
related diseases in humans [92]. 
MRP1 is normally distributed in tissues including the lung, gastrointestinal tract, 
cardiac, liver, pancreas, adrenal cortex, skin and skeletal muscle but unlike P-gp, MRP1 
is localized to basolateral membranes of polarized epithelia [101]. However, like P-gp, 
MRP1 is also expressed in pharmacological sensitive barriers and therefore exerts 




expression of both MRP1 and P-gp in sensitive tissue compartments is essential for 
cumulative tissue protection. In mice genetically lacking both P-gp (mdr1a/1b) and 
MRP1 (mrp1) genes, it was reported that a substantial fold increase in toxicity of 
chemotherapeutic drugs, vincristine and etoposide was observed in embryonic fibroblasts 
as compared to drug doses in only P-gp lacking mice [102].  
Similarly, MRP1 expression in many drug-resistant malignant and non-malignant 
diseases is a major factor to successful clinical outcomes. Especially in malignant 
diseases, MRP1 expression is contributive indicator for drug absorption and disposition. 
An unfavorable pharmacokinetic response leads to poor clinical outcome in many 
patients particularly with non-small lung cancer (NSLC), acute myeloid leukemia, 
(AML), and breast cancer [103-105]. In addition, high MRP1 expression levels have been 
linked to aggressive and multidrug resistance traits in neuroblastoma [106], and thus 
MRP1 is a key individual prognostic indicator of childhood neuroblastoma  
It can be safe to say that both P-gp and MRP1 are key contributors to clinical 
multidrug resistance in cancer due to their distribution, expression and the wide diversity 
of xenobiotic substrates transported by them. To date, several attempts to forestall MDR 
mediated by these ABC proteins remains a challenge. The prevailing challenges facing 
MDR circumvention are discussed in the next section. 
 
1.8 Current strategies for P-gp and MRP1 inhibition 
 
The rationale to circumvent MDR is to introduce compounds that will inhibit the 
activity of ABC drug efflux pumps and thus re-sensitize drug resistant tumors to respond 




the chemotherapeutic drug and improve the overall clinical outcome in many cancers. 
Although several laboratory or preclinical studies geared toward inhibiting these ABC 
proteins have shown promising outcomes, unfortunately transition and replication in 
clinical settings have not been favorable. The possible reason(s) accounting for the poor 
outcomes have been discussed in literature [107, 108], however, a brief summary of 
selected inhibitor compounds against P-gp and MRP1 and their limitations are discussed 
here.  
 
1.8.1 First generation P-gp inhibitors 
 
Over the last four decades, an extensive search for compounds against P-gp, have 
led to three pharmacological generations of P-gp inhibitors [109]. The first generation 
inhibitors were introduced by taking advantage of the polyspecificity nature of P-gp and 
included drugs already in use for other therapeutic applications such as verapamil, 
felodipine, nifedipine, chlorpromazine, quinine and cyclosporin A. Verapamil, a calcium 
channel blocker showed effective MDR reversing ability, however, its use in clinical 
trials was terminated as a result of serious cardiotoxicity. [110]. Also, verapamil required 
high plasma concentrations in order to achieve a significant P-gp blocking activity [111, 
112]. Likewise, cyclosporin A, an immunosuppressive agent did not improve treatment 
outcomes in a randomized phase II clinical trials of patients with relapsing acute myeloid 
leukemia in combination therapy with etoposide and mitoxantrone due to increased 
toxicity [113, 114]. The apparent challenge that faced this generation of inhibitors was 
their low specificity to P-gp. The reason being that they were not specifically developed 




competitively with other chemotherapeutic substrates. Coupled with the low specificity 
and different pharmacokinetic effects of these inhibitors, high doses were required for 
their potency hence the undesirable toxic effects observed. 
 
1.8.2 Second generation P-gp inhibitors 
 
Owing to the limitations of the first generation compounds, the second generation 
inhibitors were developed as derivatives from the first generation compounds through 
chemical optimizations. The second generation inhibitors lacked the original 
pharmacological activity of their parent compounds but were still hindered by low 
specificity, toxicity and pharmacokinetic effects. This generation of inhibitors include 
dexverapamil, emopamil, and PSC-833 [115]. The prominent among them, PSC-833 
(valspodar), is an analogue of cyclosporin A with no immunosuppressive activity. Studies 
have indicated that PSC-833, though was more specific and less toxic than its parent 
compound, interfered with the activity of CYP3A4 which belongs to the family of drug 
metabolizing enzymes, cytochrome P450 3A4, when used in combination with anticancer 
drugs [116, 117]. Since the metabolism and excretion of most drugs including anticancer 
drugs depend on CYP3A4 activity, inhibition of CYP3A4 by these inhibitors likely 
affected anticancer drugs in two ways: i) reduced the therapeutic effect of the drug due to 
decreased metabolism by CYP3A4 (ii) increased drug exposure or plasma drug 
concentration with resultant toxic effects due to decreased drug clearance. To overcome 
these challenges, a low cytotoxic drug dosage was required in order to limit 




insufficient to produce the desired therapeutic benefit and therefore rendered this 
generation of inhibitors clinically non-beneficial [117].  
 
1.8.3 Third generation P-gp inhibitors 
 
To solve the problems of non-specificity, low potency and toxicity, the third 
generation inhibitor compounds were designed using combinatorial chemistry and 
structural-activity relationship (SAR) approaches. Notable among these compounds that 
were able to get to the clinical trial stages include tariquidar (XR9576), zosuquidar 
(LY335979), and laniquidar (R101933) [118]. A Phase I study with tariquidar in 
combination with anticancer drug vinorelbine or P-gp fluorescent substrate rhodamine 
showed tariquidar to be a potent P-gp inhibitor with no considerable toxicity or 
pharmacokinetic effects [119]. However, in another study where tariquidar was combined 
with docetaxel in patients with lung, ovarian or cervical cancers, tariquidar was observed 
to have no clinical advantage on patients even though no intolerable pharmacokinetic 
interactions were recorded [120]. Similarly, in a randomized placebo-controlled double-
blind study of patients with newly diagnosed AML or high-risk myelodysplastic 
syndrome, zosuquidar showed no effect on the overall survival or remission rate of 
patients [121]. The possible reasons for this roadblock has been attributed to the 
following: patients selection not based on high P-gp expression, presence of other efflux 
mechanisms or not accounting for them and possible occurrence of transporter 





1.8.4 MRP1 Inhibitors 
 
Compared to P-gp, the search for MRP1 inhibitors is still in early stages since 
MRP1 was discovered years after P-gp. Additionally, the preference of MRP1 for organic 
anionic substrates have slowed down the search for MRP1-specific inhibitors. The 
selected inhibitor should possibly have anionic properties to possess a high affinity 
towards MRP1 for efficient inhibition. There is also the problem of inadequate 
intracellular drug accumulation (of the inhibitor) to cause the desired therapeutic effect 
due to inability of anionic compounds to effectively penetrate into cells. Nonetheless, 
there has been some progress made with the search for small molecule MRP1 inhibitors 
such as MK571, probenecid, sulfinpyrazone, benzbromarone, and indomethacin. MK571, 
the popular MRP1 inhibitor is an LTC4 analogue primarily developed as a leukotriene D4 
receptor antagonist for the treatment of asthma [94]. It was identified as a competitive 
inhibitor of LTC4 (and other organic anionic substrates of MRP1) and also reversed drug 
(particularly vincristine) resistance in MRP1 overexpressing cells [122]. However, 
MK571 lacks specificity as it also inhibits other organic anion uptake systems like 
organic anion transporting polypeptide or solute carrier organic anion transporters 
(OATP1B3/SLCO1B3) and other proteins in the ABCC family [94, 123]. 
Sulfinpyrazone, benzbromarone and probenecid have also been reported as organic anion 







Some P-gp inhibitors have been identified to modulate the function of MRP1. 
Among them, cyclosporin A and its analogue PSC 833 are reportedly known to inhibit 
MRP1 though with poor specificity [98]. Tyrosine kinase inhibitors (TKIs) like imatinib, 
ibrutinib, and AG1393 have also shown inhibitory activity on MRP1 [124-126]. Zheng at 
el, in a previous study demonstrated that vandetanib, a commercial orally administered 
drug inhibiting multiple receptor tyrosine kinases has dual inhibition on both MRP1 and 
BCRP- mediated drug resistance in a dose-dependent manner [125].  A recent study also 
found GSK1904529A, a potent inhibitor of insulin-like growth factor-I receptor (IGF-IR) 
tyrosine kinase, to inhibit the function of MRP1 by increasing the sensitivity of MRP1 
overexpressing MDR cells and also enhancing the efficacy of MRP1 anticancer 
substrates [127]. Novel strategies using nanoparticle drug delivery systems have also 
shown promise in MRP1 inhibition [128, 129]. Notwithstanding, the data accumulated on 
current MRP1 inhibitors, their limitations have not positioned them as potential 
candidates for clinical trials evaluation. Some common P-gp and MRP1 inhibitors are 













Table 1.1 Some common P-gp and MRP1 inhibitors 
P-gp Inhibitors MRP1 inhibitors 
First generation Second generation Third generation  
Verapamil Dexverapamil Tariquidar 
(XR9576) 
MK571 
Reserpine Gallopamil PSC KR30031 Probenecid 
Progesterone 833 (Valspodar) Cyclopropyldiben
-zosuberane 
Indomethacin 
Tamoxifen VX-710 (Biricodar) Zosuquidar 
(LY335979) 
Imatinib 
Felodipine MS-209 GF Laniquidar 
(R101933) 
Ibrutinib 
Nifedipine 120918 (Elacridar) Substituted 
diarylimidazole 
AG1393 
Erythromycin Reversin 121 ONT-093  
Flufenazine Reversin 125   
Diltiazem    
Chlorpromazine    
Quinidine    
Cyclosporin A    
 
 
1.9 Natural Products as potential source of drug strategies against multidrug 
resistance in cancer 
 
Though both P-gp and MRP1 inhibitors have failed to show success in therapeutic 
and clinical settings to date, utilizing modulators (inhibitors) to block ABC transporter-
mediated activity is still the cheapest, simplest and direct way for circumventing 




abandoned, but rather extended to include a manifold alternative strategies. Current 
alternative strategies used to target MDR include gene regulation technologies such as 
antisense oligonucleotides, RNA interference, transcriptional regulation; nanomedicine 
technologies, or a combination of both technologies, and the application of natural 
products [130, 131]. Amongst them, natural products application has garnered more 
attention in the search for MDR inhibitors. Historically, natural products and their drug 
derivatives are sources of many therapeutic agents for treatment of approximately 87% 
classified human diseases [132]. Furthermore, drugs derived from natural products are 
among the top 35 ethical drugs sold globally [133]. A study has shown that more than 
half of prescription drugs in the United States most of which fall under anti-allergic, 
analgesics and cardiovascular agents are obtained from natural products [134]. The 
extensive structural and chemical diversity of natural products make them suitable for 
semi- and total synthetic modifications. In addition, natural products are highly potent, 
safe and tolerable to use with minimal inherent toxicity compared to synthetically derived 
drugs [134]. Therefore, natural products are significant sources of new pharmacological 
leads in the drug discovery and development process. 
In the face of the challenges encountered by current P-gp and MRP1 inhibitors, 
compounds from natural origin will be more desirable for developing drug strategies to 
overcome multidrug resistance due to the advantages already mentioned. Indeed, some 
studies have referred to promising natural products-derived compounds as the fourth 
generation inhibitors. Natural products such as alkaloids, coumarins, curcumin, 
flavonoids, and terpenoids have already been reported to have inhibitory and considerable 




flavonoids, a group of plant-derived phenolic compounds were found to significantly 
enhance the accumulation of P-gp substrate, daunomycin in vitro and also conferred 
absent to moderate pharmacokinetic effect on doxorubicin, cyclosporin A and paclitaxel 
in an in vivo study [135]. In a study screening dietary flavonoids, quercetin and rutin 
were found to inhibit P-gp function and also reduced paclitaxel resistance in P-gp 
overexpressing human KB CHR 8-5 carcinoma multidrug resistance cell lines [136]. 
Coumarins and their derivatives have also shown to reverse P-gp resistance and increased 
chemotherapeutic drug bioavailability in cancer cells [137, 138]. Similarly, 
tetrahydrocurcumin (THC), the main metabolite of curcumin (derived from turmeric) 
inhibited the function of P-gp, MRP1 and BCRP and also re-sensitized their multidrug 
resistance cell lines to chemotherapeutic drugs [139].  
 
Cucurbitacins are the main natural product of interest in this work. The origin, 
structure and potential of cucurbitacins as therapeutic candidates for attenuating 
multidrug resistance in cancer are discussed in the next section.  
 
1.9.1 Cucurbitacins – origin and structure 
 
Cucurbitacins are a class of diverse compounds made up of highly oxidized 
tetracyclic triterpenoids and present in different species of the plant family Cucurbitaceae 
[140]. They are predominantly found in plants such as cucumber, honeydew melons, 
Crenshaw melon, pumpkin, cantaloupe, squash, pumpkin, angled gourd, bottle gourd, 
watermelon and colocynth. [141]. They are also known to be responsible for the bitter 




skeleton (Figure 1.7) or basic triterpenoid (carbon-30 compound with IUPAC name 
19(10–9ß)-abeo-5α-lanostanes) built from six isoprene units with oxygen substitutions at 










Figure 1.7 Cucurbitacin skeleton [141]. 
 
Cucurbitacins are classified into twelve types designated A to T. The diversity of the 
different cucurbitacin classes is based on the positions of substituent molecules 
(hydroxylated, unsaturated, keto, glycosyl and acyl groups) attached to them. [142]. As 
reported by Miro, cucurbitacins A, B,C, D, E, F, I, O and Q contain unsaturated 
substitutions at carbon position 23 (C-23). On the other hand, cucurbitacins G, H, J and K 
are typically unsubstituted except for a hydroxyl group on C-24. In general, the basic 
structure of cucurbitacins is characterized by a gem-dimethyl group at C-4 and an 
isopropyl group at C-24. There is also presence of methyl groups at positions C-9,C-




[140]. Cucurbitacins can also be identified based on whether they are naturally occurring 
or products from enzymatic reactions. [140]. Cucurbitacins B and E are believed to be the 
naturally occurring cucurbitacins in plants from which the other types are generated 
through metabolic processes. For instance, cucurbitacins A, C, D, F, G, and H, are 
products from metabolism of cucurbitacin B while cucurbitacins I, J, K, and L are 
derived from metabolism of cucurbitacin E [140]. Furthermore, cucurbitacins B and D 
could be converted to their reduced forms, 23,24-dihydrocucurbitacin B and 23,24-
dihydrocucurbitacin D, respectively.  
 
1.9.2 Cucurbitacins Antitumor Activities 
 
Cucurbitacins (Cucs) were earlier used for treatment of liver diseases such as 
jaundice, cirrhosis and hepatitis in folk medicine due to their natural hepatoprotective 
properties [142]. Besides this property, cucurbitacins also possess other important 
pharmacological traits and were thus utilized as purgatives, anti-inflammatory and 
antimicrobial agents [143]. The antitumor activity of cucurbitacins was discovered more 
than 50 years ago, however, due to serious toxic effects in humans, their usage 
subsequently diminished [144]. Fortunately, developments leading to in vitro anticancer 
drug screening on 60 human tumor cell lines by the National Cancer Institute (NCI-60) 
[140] restored their potential as prospective source of anticancer compound candidates. 
To understand the biological mechanism of cucurbitacins, recently, more research have 
focused on their cytotoxic and antitumor activities.  
Cucurbitacins B, D, E and I are amongst the widely explored cucurbitacins in 




antitumor activities in various cancer profiles both in vitro and in vivo.  Cucurbitacin B 
particularly, has exhibited potent cytotoxic and antitumor activities in more than 100 
tumor panels e.g. breast, colon, leukemia and lung cancers [146, 147]. The antitumor 
activity of cucurbitacin B has been attributed to its ability to induce various phases of cell 
cycle arrest and apoptosis by modulating several signaling pathways in tumor cells. For 
instance, cucurbitacin B induced G2 arrest and caspase-dependent apoptosis in human 
colon adenocarcinoma SW480 cells in a reactive oxidative species (ROS)-dependent 
manner while activating caspases and suppressing the expression of cyclin B1 and 
cdc25C proteins [148]. Cucurbitacin B has also displayed in vitro and in vivo 
antiproliferative and apoptotic activities through JAK/STAT inhibition mechanism in 
human pancreatic cancer cells [149]. Treatment of breast cancer cell lines (MCF-7 and 
MDA-MB-231) with cucurbitacins B and E glucosides extracted from the leaves of 
Citrullus colocynthis inhibited tumor growth through cell cycle arrest and apoptosis 
[150]. 
Similarly, a plethora of reports have so far demonstrated cucurbitacin D has 
inhibitory effect on leukemic, hepatic, colon, lung, breast and central nervous system 
carcinoma cell lines [140]. In a recent study, cucurbitacin D suppressed metastasis in 
prostate cancer cells via a glucose regulation mechanism [151]. Cucurbitacin E in a 
similar study was reported to play a significant role in microtubule skeletal elements 
(actin and vimentin) disruption, which are responsible for tumor aggression in prostrate 
carcinoma [145, 152]. In addition, a combination of cucurbitacin E with doxorubicin 
treatment enhanced the chemotherapeutic and collective antitumorigenic effect both in 




through inhibiting the PI3KAkt signaling pathway in multiple cancer cell lines have been 
reported for cucurbitacin C [154]. Cucurbitacin I has shown effective tumor growth 
inhibition in breast and prostate carcinoma cell lines (MDA-MB-231, MDA-MB-468, 
Panc-1), both in vitro and in vivo [145].  
 
1.9.3 Cucurbitacin-inspired estrone analogs (CIEA) 
 
Notwithstanding the numerous evidence showing the anticancer activities of 
cucurbitacins, they are still limited as sources of pharmacological candidates due to the 
following:  
a) Cucurbitacins are available at only minute concentrations in their natural sources 
(plants), therefore isolating them in large concentrations is tedious and usually 
unsuccessful.   
b) The structural complexity and diversity in functional groups or pharmacophores 
of cucurbitacins makes total synthesis difficult.  
c) Cucurbitacins induce toxic adverse effects in mammals even at low doses.  
To overcome these challenges and also generate them as suitable drug candidates, the 
Halaweish group utilized a steroidal scaffold, estrone, as starting skeleton before 
installing the biologically active pharmacophores of cucurbitacins. The approach was 
possible due to the similarity between cucurbitacin and estrone skeletons. The estrone 
chemical structure contains a tetracyclic system that mimics the cucurbitacin skeleton 
(Figure 1.8). However, the two structures differ by the presence of aliphatic ring and a 
gem-dimethyl group at C-4 in the cucurbitacin structure, which is absent in the estrone 




chain of cucurbitacins which is a significant pharmacophore for their biological activity 
was assembled to create different estrone derivatives. The intent was to create new 
estrone derivatives that have superior pharmacological activity but lack their estrogenic 
activity. Further structural modifications such as double bond installation at C-16/C-17, 
hydroxyl group substitution at C-3 with methoxy and sulfamoyl groups [155] were also 
used to generate different derivatives of cucurbitacins-inspired estrone analogues (CIEA). 
Figure 1.8 Design strategy for cucurbitacin-inspired estrone derivatives developed by the 
Halaweish group.  
 
1.10 Biochemical Approaches for Studying ABC Transporter Modulators  
 
ABC transporters have the ability to recognize and transport a broad range of 
molecules that include therapeutically important drugs and thus play an active role in 
drug pharmacokinetics (absorption, distribution, metabolism, excretion and toxicity 
(ADMET)). Compounds that interact with and influence the activity of ABC transporters 




substrates (carried across the plasma membrane by the transporter), inhibitors, (impede 
the transport of other compounds), inducers (amplify transporter expression) or activators 
(improve transporter activity) however, one compound can have overlapping mechanisms 
of action [156]. The mechanisms of action presented by different modulators are 
important for therapeutic exploitation to overcome MDR in cancer. For compound 
interactions with ABC transporters, a substrate drug is usually used as ‘probe’ to 
investigate potential inhibitors. The mechanism of inhibitors to block transporter 
mediated efflux of substrates can be one of the following ways: i) by direct inhibition of 
the transporter binding sites and thus preventing the binding of the substrate, ii) inhibition 
of ATP binding or hydrolysis; or iii) inhibiting the coupling of ATP hydrolysis to 
substrate translocation [156]. One of the most studied substrate-inhibitor interaction with 
ABC transporter systems is the drug-drug interaction involving digoxin and quinidine 
with P-gp. A study reported that quinidine increased plasma digoxin levels in both P-gp 
overexpressing cell lines and mouse models by inhibiting P-gp mediated transport of 
digoxin into the gut and kidneys which enhanced the bioavailability of digoxin [157]. 
Digoxin is a cardiac glycoside and function as both a substrate and inhibitor of P-gp. 
Therapeutically, digoxin is said to have a narrow effective window in which case 
coadministration with P-gp inhibitors may result in toxic drug accumulations. In such 
instance, inducers or activators can be useful to reduce toxicity to target tissues. Inducers 
are involved in increasing transporter expression whereas activators stimulate transporter 
efflux activity. Dexamethasone, doxorubicin, vinblastine and rifampicin are inducers for 
both P-gp and MRP1 [91]. P-gp inducers are said to be regulated by various nuclear 




of the transport or (b) stimulating the affinity of ATP for NBDs to increase ATP binding; 
or inducing TMDs conformational changes as a result of substrate-specific binding to the 
transporter [158, 159].  Inducers and activators have been used to detoxify potentially 
cytotoxic compounds in many cellular models such as the blood-brain barrier, the 
cardiovascular system and liver [91].  
Thus, for novel drug candidates targeting multidrug resistance in cancer, it is 
important to profile them with ABC transporters to elucidate their mode of action and 
toxic effects, which can be used to predict their drug interaction in vivo. In view of the 
important roles played by ABC transporters in the pharmacokinetics of various drugs, the 
US Food and Drugs Administration (FDA), has recommended the evaluation of various 
drug candidates in vitro to determine their interaction with selected ABC transporters 
[160]. Some established in vitro assays for studying ABC transporter-drug interactions 
applicable to this research are discussed in the sub sections. 
 
1.10.1 High Content Fluorescence-based Screening 
 
High throughput screening (HTS) is among one of the first techniques used in the 
drug discovery process especially in the pharmaceutical industry to investigate the 
interaction of new chemical entities with their biological targets.  HTS performed in vitro 
provides low-cost alternatives to unwarranted animal testing which might be painstaking 
and time consuming. HTS assays have been employed to investigate interaction of large 
compound libraries with ABC transporters.  Lee et al, using a luminescence-based HTS 
tested a library of 10,804 compounds on a P-gp overexpressing colchicine-selected 




incorporation of instruments with optical sensitivities for imaging-based screening have 
more significantly improved conventional HTS techniques. Ansbro et al. reported a high 
content screening (HCS) assay which was used to evaluate the activity of a kinase 
inhibitor library on P-gp mediated calcein-AM efflux in MDR P-gp overexpressing KB-
V1 cell using a fluorescent and phase-contrast live cell imaging system [162]. The phase-
contrast system allowed simultaneous identification of cell viability and density before 
and after treatments, which helped to monitor cytotoxic effects in cells in situ. In 
comparison, the fluorescent imaging system enabled live cell capture and quantification 
of fluorescent images against a background fluorescence through segmentation masks to 
obtain intracellular fluorescence intensities as a measure of the performance of the 
compounds of interest. The HCS also has the advantage of not requiring multiple 
washing procedures and therefore tenable for in situ cell-based systems. Recently in our 
group, a high content imaging-based efflux assay was developed to investigate the 
interaction of a 386 anti-cancer compound library with MRP1 using calcein-AM and 
doxorubicin as fluorescent reporters in two independent studies respectively [163, 164]. 
The assay was effective in identifying novel inhibitors for MRP1. In this research study, 
the high content imaging-based efflux assay was replicated to screen a novel compound 
library of CIEA to identify inhibitors of P-gp and MRP1.  
 
1.10.2 Flow Cytometry-based Accumulation or Efflux assays 
 
Flow cytometry (FC) is a one of the common cell-based assays for studying the 
functional characterization of ABC transporter-drug interactions. FC makes use of 




RNA. Moreover, specific antibodies tagged with fluorescent dyes can be used to target 
specific cell membrane or intracellular proteins [91]. In the FC principle, fluorescent 
particles (fluorochromes) present in cells stained with the fluorescent material are able to 
undergo excitation at higher energies when passed through a light source. Upon returning 
to their non-excited states, the fluorochromes emit light at specific wavelengths 
depending on the dye used. The fluorescence emitted is detected by specific filters and 
counted by a flow cytometer. The technique allows for simultaneous measurements of 
different cellular properties with several fluorochromes excited by a single laser to yield 
different emission wavelengths. The activity of efflux transporters may be evaluated on 
the basis of fluorescent dye accumulation/efflux or both performed on cell suspensions or 
monolayers [165]. In both assays, the accumulation or efflux of the specific ABC 
transporter fluorescent substrate over a time period is measured in the presence or 
absence of their specific inhibitors or activators. In accumulation assays, fluorescent dye 
accumulation is higher in cells with high transporter expression under conditions where 
transporter is inhibited compared to the control (absence of inhibition). In contrast, 
extracellular dye concentrations are measured in efflux studies as an indicator of 
transporter activity. Here, the amount of dye effluxed is reduced under transporter 
inhibition conditions compared to no treatment conditions. For both studies, transporter 
activity can be compared with wild-type or parental cells that do not have transporter 
expression [165]. Some common fluorescent substrates used in P-gp functional studies 
include rhodamine 123, doxorubicin, daunorubicin, or calcein-AM [166]. Both 
doxorubicin and calcein-AM or specific dyes like BCECF can be used as substrates for 




applicability of flow cytometry, most fluorescent reporters may be limited to specific 




1.10.3 In Silico Molecular Docking Studies 
 
In silico docking models are quick, economical and primary screening platforms 
for predicting ligand-receptor interactions for novel pharmacophores in drug 
development and discovery. The docking process involves generation of suitable 
conformations of both ligands and receptors which are then docked using simulations to 
discover lead compounds with the best binding interactions. Docking reveals both the 
quantitative and qualitative characteristics of ligand binding modes to active sites of 
receptor molecules using various applications [136]. Various docking models have been 
used to predict binding interactions of potential modulators for P-gp, MRP1 and BCRP 
which has allowed prediction of modulator binding interactions with their respective 
transporters [167-169]. 
 
1.10.4 Fluorescence Spectroscopy – FRET 
 
Fluorescence spectroscopy is an indispensable molecular probing tool used to 
investigate structural-based interactions between cellular molecules. In fluorescence 
resonance energy transfer (FRET), the transfer of energy between two fluorophores is 
used as a measure of their interaction. One fluorophore (donor) in an excited state is able 
to transfer its energy to a nearby fluorophore (acceptor) in close proximity before 




fluorophores (the donor and acceptor), the greater the energy transfer or FRET efficiency 
and greater the sensitivity to detect significant structural changes between the two 
molecules. There is also a spectral overlap between donor emission and acceptor 









Figure 1.9  Diagram illustrating the fundamental principle of FRET [170] 
 
FRET-based spectroscopy has been used as a key biochemical approach to study real 
time structural characteristics in ABC transporters using fluorescent proteins and 
powerful imaging techniques. A study by Verhalen et al. using FRET spectroscopy was 
able to elucidate the dynamics of ligand-induced structural rearrangements in the NBD 
catalytic cycle of P-gp [171]. Recently, our group was able to develop genetically 
engineered unique biosensors to identify novel modulators for MRP1 based on 









1.11 Research Strategy and Significance 
 
Current generation P-gp and MRP1 inhibitors are limited by toxicity, lack of 
specificity and low therapeutic effect even though they have shown promising potential 
in some clinical studies. The absence of no successful P-gp or MRP1 inhibitor in clinical 
settings has prompted more research to focus on developing and discovering novel 
compounds from natural products as desirable alternatives due to the less toxic and 
structurally diverse properties of naturally-derived chemical entities. To discover novel 
drug candidates with superior and safe pharmacological outcomes towards specific 
cancers, the Halaweish group designed a library of estrone derivatives known as 
cucurbitacin-inspired estrone analogues (CIEA). In the context that the CIEA compounds 
have been developed as safe pharmacological candidates for cancer treatment and the fact 
that cucurbitacins are less explored as potential ABC transporter inhibitors, our lab 
collaborated with the Halaweish group with the aim to test the effect of the new CIEA 
compounds on selected ABC transporters. We posed the question whether these novel 
compounds will be more effective than currently known inhibitors of P-gp and MRP1. 
Our primary goal was to identify novel inhibitors for P-gp and MRP1 from the large 
library of CIEA. To address this goal, the following specific objectives were established: 
 
Objective 1: Profiling a library of 81 CIEA compounds against P-gp and MRP1 




activity assay. The inhibition of P-gp by the CIEA compounds was evaluated by using 
calcein AM as fluorescent probe whereas MRP1 inhibition was detected using two 
different fluorescent probes, doxorubicin and calcein red orange. The percent inhibition 
by the CIEA compounds were compared with standard P-gp and MRP1 inhibitors to 
identify potential hits. 
 
Objective 2: Validation of inhibition activity of the hit compounds identified from the 
HCS. In this objective, flow cytometry-based and confocal microscopy-based 
accumulation assays were used to confirm the functional activity of P-gp and MRP1 in 
the presence of the hit compounds. 
 
Objective 3:  Evaluation of the MDR reversing property of the hit compounds in 
multidrug resistant P-gp or MRP1 overexpressing cells towards selected anticancer 
agents using cell viability assays. 
 
Objective 4: Investigating the effects of hit compounds on P-gp or MRP1 protein 
expression levels using western blot technique. 
 
Objective 5: Investigation of direct interaction of the hit compounds with P-gp or MRP1 
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Characterization of cucurbitacin-inspired estrone analogues as novel inhibitors for 




Multidrug resistance (MDR) remains a major challenge to cancer therapy and it is mainly 
attributed to the overexpression of membrane bound ATP-binding cassette (ABC) 
superfamily of transporters. Permeability glycoprotein (P-gp), a member of the ABC 
transporter family contributes to multidrug resistance in various cancers by reducing the 
efficacy and bioavailability of anticancer drugs. Therapeutic strategies to overcome P-gp 
have failed due to lack of specificity, low potency and severe toxicity. To identify novel 
inhibitors for P-gp, a high content fluorescence-based screening assay initially developed 
by our group was used to screen a library of 81 novel cucurbitacin-inspired estrone 
analogs (CIEAs). Defining a hit as a compound showing at least 50% percent inhibition, 
the assay identified 8 compounds as inhibitors of P-gp using calcein-AM as fluorescent 
reporter. The hit compounds demonstrated 50-85% range percent inhibition of P-gp-
mediated calcein efflux. Flow cytometry and confocal microscopy-based accumulation 
assays were used to confirm inhibition of P-gp efflux activity. The ability of the 
compounds to reverse resistance of P-gp overexpressing cells against vincristine, 
paclitaxel and etoposide was also tested. The compounds were most effective in reversing 
etoposide resistance in HEK293/P-gp cells by reducing resistance fold from 173 to 
between 33-50 fold.  Nonetheless, the identified compounds had no effect on P-gp 
expression. Using in silico molecular docking and FRET-based spectroscopic analyses 




results presented in this study suggest the use of cucurbitacin-inspired estrone analogues 
as promising leads for future drug optimization against multidrug resistance in cancer. 
Keywords: P-gp, ABC transporter, multidrug resistance, cancer therapy, anticancer 





















A key problem leading to chemotherapeutic failure in cancer treatment is the 
development of multidrug resistance (MDR). MDR is the insensitivity of tumor cells to 
many anticancer agents which are different in structure, function or mechanism of action 
[1]. Several mechanisms including decreased drug uptake, increased drug efflux, drug 
inactivation, drug target alteration, DNA damage repair and cell death inhibition have 
been reported to promote drug resistance [2, 3]. However, the best studied and major 
underlying mechanism of MDR in malignant tumors is that due to overexpression of 
mammalian ATP-binding cassette (ABC) transporters [4]. ABC transporters represent the 
ubiquitous family of transmembrane efflux pumps that utilize energy derived from ATP 
binding and hydrolysis to drive the transport of molecules against their concentration 
gradient across the plasma membrane [5-7]. To date, 48 human ABC transporter genes 
have been reported and they are classified into seven subfamilies, ABCA-G [8]. Amongst 
the ABC transporters, P-gp (P-glycoprotein/ABCB1), MRP1 (multidrug resistance 
protein 1/ABCC1) and BCRP (breast cancer resistance protein/ABCG2) are the main 
drug transporters implicated in many MDR related cancers. All three transporters 
facilitate active efflux of structurally and pharmacologically unrelated chemotherapeutic 
agents across the plasma membrane limiting intracellular drug accumulation and drug-
mediated cancer cell death. [3]. 
P-gp, the first member of the ABC transporters discovered and the most 
characterized transporter is a 170 kDa protein encoded by the human MDR1 gene. The P-
gp polypeptide is made up of two homologous halves, each composed of one membrane 




distribution of P-gp plays a major role in protecting tissues from xenobiotics and harmful 
metabolites. P-gp is typically but not exclusively, localized at the apical membranes of 
epithelial cells of the colon, small intestines, liver, pancreas, kidney and uterus [11, 12]. 
Thus, intestinal P-gp has been suggested as the primary barrier for orally-administered 
drug substrates due to limiting the bioavailability of these drugs in the body [13].  
Furthermore, high expression levels of P-gp have been reported in up to 50% of gastric 
cancers [14]. In humans, P-gp is biologically localized at important pharmacological 
barriers such as the blood-brain and blood-nerve barriers [5, 13, 18, 22].  Expression of 
P-gp at these sites is consistent with its anatomical drug-efflux role in protecting sensitive 
and vital tissues from toxic exogenous compounds [10, 15-19]. More critically, P-gp 
expression at the endothelial cells of the blood-brain barrier (BBB) is physically 
necessary to block the net penetration of xenobiotics into the brain tissue [20]. The 
absence of this can result in up to 10 to100 fold increase in drug penetration in the brain 
which is clinically undesirable [5, 17, 18, 21]. However, this could be of therapeutic 
relevance to clinically important drugs such as antiepileptics and antiemetics targeting the 
brain or central nervous system (CNS) [22]. In the blood-testis and fetal-maternal 
barriers, P-gp is expressed in stage-specific manner and plays an analogous function as in 
the BBB [5]. In general, P-gp overexpression is associated with poor chemotherapy 
outcome at both primary diagnosis and disease relapse stages of several cancers such as 
leukemia, lymphomas, adult and childhood sarcomas and neuroblastomas [23-26]. Apart 
from its drug-efflux function, P-gp also plays a significant role in other cellular processes 
such as intracellular cholesterol trafficking and lipid transport, cell immunity, apoptosis 




P-gp transporter has broad substrate polyspecificity and ability to distinguish 
many compounds from as tiny as 330 to 4000 Da [9, 28, 29]. Additionally, P-gp is able to 
extrude many relatively hydrophobic substrates partitioned in the lipid bilayer from the 
plasma membrane into the extracellular aqueous matrix [28, 30]. Two mechanistic 
models accounting for these two interesting features have been hypothesized. The first 
proposes a model where the transporter creates a hydrophilic pathway and drugs are 
effluxed from the cytosol to the extracellular matrix through the middle of a pore 
protecting the hydrophobic lipid phase [31] . The second model describes the transporter 
as a ‘flippase’ that intercepts a substrate and flips it from the inner cell leaflet to the outer 
and into the extracellular matrix as the substrate travels through the lipid membrane [32]. 
It is not surprising that P-gp transports various clinically significant drugs, including 
anticancer agents such as vinca alkaloids, anthracyclines, epipodophyllotoxins, taxanes, 
immunosuppressive drugs, cardiovascular agents, anthelmintics, and steroids out of the 
cell [22]. Considering that P-gp recognizes and transports such broad range of 
structurally unrelated compounds, finding the appropriate P-gp inhibitor to improve the 
pharmacological benefit of many commonly used xenobiotics still remains a challenge.    
Several attempts to circumvent P-gp mediated multidrug resistance with small 
molecular entities, a process known as chemosensitization have given rise to various 
pharmacological classes of P-gp inhibitors [33, 34]. The first generation P-gp inhibitors 
were mostly drugs originally developed for other therapeutic applications such as 
immunosuppression, antibiotic and cardiacs [35]. These P-gp inhibitors including 
verapamil, cyclosporin, nifedipine, chlorpromazine, quinine and elodipine have 




success was limited by toxicity and off-target effects [37, 38]. Verapamil, a calcium-
channel blocker was reportedly associated with serious cardiotoxicity as it requires 
relatively high plasma concentrations for efficacy [39]. Also, some of these inhibitors 
were reported to interfere with the activity of CYP3A, an isoform of the drug 
metabolizing enzyme cytochrome P450 [40, 41], suggesting that these inhibitors may 
have similar substrates with CYP3A and therefore interfered with the pharmacokinetics 
of chemotherapeutic drugs in combinatorial therapy. The second generation of inhibitors 
such as dexverapamil, emopamil and valspodar [10, 42, 43] derived from the first 
generation compounds were introduced as an improvement on dose-potency and toxicity 
but still interfered with CYP3A activity [10]. The search for compounds to overcome the 
second generation limitations, resulted in compounds designed using combinatorial 
chemistry and structure-activity relationship approaches [10, 11, 44, 45]. These 
inhibitors, the third generation compared with the first- and second generations were 
more specific inhibiting P-gp function with no significant impact on CYP3A activity and 
include drugs such as tariquidar, zosuquidar and laniquidar [10]. Disappointingly, 
outcomes from clinical trials using these inhibitors were not clinically beneficial. A study 
done by Kelly et al, revealed that co-administration of tariquidar (XR9576) with 
docetaxel did not improve overall survival rate of patients with metastatic cancers even 
with no toxicity [46]. Another study showed zosuquidar to be ineffective towards newly 
diagnosed acute myeloid leukemia adults (older than 60 years) [47]. The reasons for the 
lack of therapeutic benefits from clinical trials have been attributed to patients selection 
not based solely on high P-gp expression, presence of other efflux mechanisms or lack of 




polymorphisms that may lead to interpatient variability [48]. Thus, it appears future trials 
of current generation P-gp inhibitors will be limited by their therapeutic benefit hence 
alternative strategies should be sought. 
Presently, the fall back to natural products as source for novel compounds has 
optimistically advanced in the search for MDR modulation agents. Natural products are 
important sources for new chemical entities (NCEs) in contemporary drug discovery and 
design due to their diversity and amenability to semi- and total synthetic modification 
[49]. Cucurbitacins (Cucs) are natural products with oxidized tetracyclic triterpenoids 
derived from different species of the plant family Cucurbitaceae; with the main types 
being cucurbitacins A to T [50]. Cucurbitacins are well-known to possess significant 
pharmacological properties that have been explored in the treatment of various illness. 
The hepatoprotective activity of cucurbitacins has been demonstrated by Bartalis and 
Halaweish on HepG2 HSC-T6 cell lines [51]. Accumulated data have shown 
cucurbitacins remarkable antitumor activities in various cancer profiles both in vitro and 
in vivo. Particularly, cucurbitacin B has potent cytotoxic and antitumor activity in more 
than 100 tumor panels e.g. breast, colon, leukemia and lung cancers [52, 53]. 
Cucurbitacin B has been reported to induce G2 arrest and caspase-dependent apoptosis in 
human colon adenocarcinoma SW480 cells in a reactive oxidative species (ROS) – 
dependent manner while activating caspases and suppressing the expression of cyclin B1 
and cdc25C proteins [54]. Similarly, cucurbitacin D has reportedly shown to exert 
inhibitory activities in leukemic, hepatic, colon, lung, breast and central nervous system 
tumor cell lines [55]. In a recent study, cucurbitacin D suppressed metastasis in human 




reported to disrupt microtubule skeletal elements (actin and vimentin) responsible for 
tumor aggression in prostrate carcinoma [57, 58]. In a combination therapy with 
doxorubicin, cucurbitacin E enhanced the collective chemotherapeutic and 
antitumorigenic effects in gastric cancer both in vitro and in vivo [59]. Cucurbitacins C, I 
and Q are known to have antiproliferative and antitumor activities in various cancers [58, 
60]. Collectively, these reports position cucurbitacins and their derivatives as prospective 
drug candidates in cancer treatment. However, evaluation of cucurbitacins and its 
derivatives as sources of ABC transporter (s) modulating agents is less explored.  In this 
work, we reckoned that exploiting the anticancer properties of cucurbitacins-derived 
small compound analogues may position them as drug candidates for P-gp modulation 
against multidrug resistance in cancer. 
Using molecular modeling and structural activity relationships (SAR), the 
Halaweish group synthesized novel compounds known as cucurbitacin-inspired estrone 
analogs  (CIEAs) from cucurbitacin using estrone as starting scaffold. These compounds 
were designed to dual target epidermal growth factor receptor (EGFR) and mitogen 
activated protein kinase (MAPK) pathways involved in cancer proliferation. In this study, 
we investigated the effects of the CIEAs on P-gp activity. A library of 81 CIEA were 
screened using a high content fluorescence-based transporter activity assay previously 
developed in our lab [61]. From the high content fluorescence-based inhibition 
experiment using calcein-AM as P-gp substrate, 8 CIEAs were identified as potential P-
gp inhibitors. Using established cell-based functional assays, we validated the inhibitory 
activity of the identified inhibitors and also demonstrated their ability to sensitize 




cell viability assays. The direct interaction of the identified compounds with P-gp was 
also demonstrated. 
 




Thiazolyl blue tetrazolium bromide (MTT), doxorubicin and verapamil were 
purchased from Sigma-Aldrich (St. Louis, MO). Calcein-AM was acquired from Corning 
Life Sciences (Corning, NY). Vincristine and etoposide were procured from Cayman 
Chemicals (Ann Arbor, MI) while paclitaxel was  purchased from MedChemExpress 
(Monmouth Junction, NJ). Cucurbitacin-inspired estrone analogue (CIEA) compounds 
were generously provided by Dr. Fathi Halaweish (South Dakota State University, 
Brookings, SD).  
 
2.2.2 Cell lines and cell culture 
 
HEK293/pcDNA3.1 and HEK293/P-gp, were kindly provided by Dr. Suresh V. 
Ambudkar (NIH, Bethesda, MD).  HEK293T cells were gifted by Dr. Adam Hoppe 
(South Dakota State University, Brookings SD). HEK293 cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (GE Healthcare Life Sciences, Logan, 
UT) complemented with 10% (v/v) fetal bovine serum (FBS) (HycloneTM, GE Healthcare 
Life Sciences). Cell cultures were maintained at 37 °C in a humidified incubator supplied 




2.2.3 High content fluorescence-based transporter activity assay for screening of 
CIEA library 
 The assay was previously developed and optimized as reported in [61]. 
Fluorescence-based inhibition screening of the 81 CIEA compound library was 
performed on HEK293/pcDNA3.1 and HEK293/P-gp cells using calcein-AM as 
fluorescent substrate and reversan as positive inhibitor control. Cells were seeded at 
density of 8 x 103 cells per well in 100 μL culture medium placed in a polymer-based 96-
well optical-bottom plate (Thermo Fisher Scientific, Waltham, MA) coated with poly-D-
lysine (Sigma-Aldrich, St. Louis, MO) and incubated overnight. The next day, the culture 
medium was removed and replaced with 80 µL serum-free medium. Drug treatment was 
performed by adding DMSO (0.2% final concentration) as a negative control, reversan 
(15 μM final concentration) as positive control or test compounds (10 μM final 
concentration) and incubated at 37 °C for 30 min. Fluorescent substrate treatment was 
performed by adding calcein-AM (0.25 μM final concentration). After 1 h, media 
containing treatment were removed and cells were washed once with PBS and suspended 
in 100 µL PBS containing 10 mM HEPES and 4.5% glucose prior to analysis.  
 An ImageXpress Micro XLS Widefield High-Content Analysis System 
(Molecular Devices, Sunnyvale, CA) equipped with a 0.70 numerical aperture 60x 
objective was used to acquire fluorescent images. Two independent experiments were 
conducted. Images were obtained using an FITC filter for calcein-AM with excitation and 
emission wavelengths of 482/35 nm and 536/40 nm respectively with exposure time set 
for 100 ms. Negative and positive controls were included in every two columns to 




over time. Fluorescent images were analyzed using the MetaXpress software (version 
5.10.41, Molecular Devices) based on segmentation of fluorescent objects in the FITC 
channel. A custom application component depending on the ‘Find Blobs’ module was 
applied to differentiate fluorescent objects against background fluorescence by 
employing segmentation masks as per parameters set for object size.  
 
2.2.4 Calcein-AM accumulation assay 
 
The ability of the identified CIEA compounds to inhibit P-gp-mediated calcein-
AM efflux was confirmed using flow cytometry.  HEK293/pcDNA3.1 and HEK293/P-gp 
cells were prepared in serum free DMEM culture media at 7x105 cell density per mL and 
treated with DMSO (0.2% final concentration), negative control, verapamil (10 μM final 
concentration) as positive control or test compounds (10 μM final concentration) and 
incubated at 37 °C for 10 min. Cells were then treated with calcein-AM (0.25 μM final 
concentration) and incubated for 30 min. Post incubation, the reaction was halted by 
addition of 3 mL ice-cold PBS. Cells were pelleted, washed twice with ice-cold PBS, 
resuspended in 1% paraformaldehyde (in ice cold PBS) and kept on ice for analysis. 
Intracellular fluorescence was determined using BD Accuri C6 flow cytometer (BD 
Biosciences, San Jose, CA) equipped with 488 nm argon laser and detected with 533/30 
nm band pass filter for calcein-AM. Each experimental treatment was duplicated and 
fluorescent values expressed as mean of 10,000 events.  Results were collated from three 






2.2.5 Doxorubicin accumulation assay  
 
HEK293T cells were seeded in a 6-well plate, each well containing a poly-D-
lysine coated (ethanol sterilized) cover glass with 2.5 x 105 cells in 2 mL culture medium. 
After incubation overnight, cells were transiently transfected with a two-color P-gp-GFP-
RFP expression vector (GR 678) using jet Prime Transfection Reagent (Polyplus – 
transfection SA, Illkirch, France) in accordance with manufacturer’s protocol. Following 
48 h after transfection, cells were pretreated with test compounds (10 µM) for 30 min, 
before incubation with doxorubicin (10 µM)  for 1 h. Cells were preserved in a buffer 
(4.5% glucose, 10mM HEPES and PBS containing Ca2+ and Mg2+) before analysis. 
Intracellular fluorescence accumulation was viewed using an iMIC digital 
microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with a 1.35 
numerical aperture 60x oil-immersion objective. GFP and doxorubicin were excited at 
445 nm with emission bands at 537/26 nm and 605/64 nm respectively. RFP was viewed 
in the 605/64 nm band channel after excitation at 561 nm. Images were processed with 
ImageJ (NIH, Bethesda, MD). 
 
2.2.6 Drug resistance reversal studies 
 
The potential of the identified CIEA compounds to reverse resistance of 
HEK293/P-gp cells against P-gp anticancer substrates (vincristine, paclitaxel and 
etoposide) were tested using MTT colorimetric assay. HEK293/pcDNA3.1 and 
HEK293/P-gp cells at a density of 5 x 104 cells/well in 100 µL culture medium were 




treated with 50 µL (in culture medium) test compounds (at non cytotoxic concentrations) 
or 0.2% DMSO for 1 h before addition of 50 µL drug substrates (vincristine, paclitaxel 
and etoposide) at varying concentrations. Following incubation for 72 h,  100 µL of 
culture medium was removed and cells were treated with MTT dye (5 mg/mL in PBS) for 
4 h to allow viable cells to change the yellow-colored MTT into dark-blue formazan 
crystals. The MTT formazan product was dissolved with 100 µL 15% SDS containing 10 
mM HCl. Cell viability was determined by measuring absorbance at 540 nm with a plate 
reader, Hidex Sense Beta Plus (Turku, Finland). Three independent experiments were 
performed with each done in triplicates.  
 
2.2.7 Western blot analysis 
 
Briefly 7 x 105 HEK293/P-gp cells were seeded in a 6-well plate at 2 mL per well 
and incubated overnight before treatment with 10 µM test compounds. After 48 h, cell 
lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher 
Scientific, Waltham, MA) containing 1x Halt Protease Inhibitor Cocktail. Lysate protein 
concentrations were determined using Pierce bicinchoninic acid (BCA) Protein Assay. 
Proteins (20 µg) from each treatment were subjected to electrophoresis on 10% sodium 
dodecyl sulfate polyacrylamide gels before being transferred to a PVDF membrane 
(EMD Millipore, Burlington, MA). The membrane was blocked and incubated overnight 
at 4 °C with monoclonal P-gp antibody [C219] (GTX23364, GeneTex) and anti-α-tubulin 
antibody (Sigma-Aldrich) at 1:250 and 1:5000 dilutions, respectively. Incubation with 
secondary antibody (horseradish peroxidase-conjugated goat anti-mouse immunoglobulin 




temperature. ABCB1 proteins were developed using western blotting luminol reagent 
(Santa Cruz Biotechnology, sc-2048) and imaged with LI-COR Odyssey Fc Imaging 
System. Protein band densities were analyzed with Image Studio Lite version 5.2 (LI-
COR Biotechnology, Lincoln, NE) software. Uneven sample loading was corrected using 
the intensity of corresponding protein band relative to α -tubulin (loading control) band. 
Two independent experiments were conducted and statistical testing was performed at 
5% level of significance. 
 
2.2.8 In silico molecular docking studies 
 
The identified CIEA compounds (ligands) were prepared for docking by 
generating three-dimensional conformations using Chem 3D Ultra 12.0 software 
[Chemical Structure Drawing Standard; Cambridge Soft Corporation, USA (2010)], 
accompanied by energy minimization using MMFF94 force field application. Human 
ABCB1 homology model based on refined mouse ABCB1 was obtained from protein 
data bank (PDB code: 4M1M). After bound molecules and ligands were eliminated, the 
protein drug-binding pocket was prepared for docking using OpenEye software. Docking 
was performed with  FRED (version 2.5.1.4) and VIDA application (version 4.1.2) was 
used to visualize binding poses of the ligand-receptor complex.  
 
2.2.9 Fluorescence spectroscopic analysis 
 
Membrane vesicles were prepared as previously described [61, 62] with slight 




plasmid, GR678 were first cultured in 150 mm cell culture dishes. After 7 days or about 
98% cell confluency, the cells were pelleted and stored at −80 °C till ready for use. For 
membrane vesicle preparation, the frozen pelleted cells were initially thawed and 
maintained in 10 mL homogenization buffer (250 mM sucrose, 50 mM Tris.HCl, 0.25 
mM CaCl2, pH 7.4) supplemented with 1 tablet protease inhibitor (Santa Cruz 
Biotechnology, Dallas, TX) and 10 µL benzamidine (200 mg/ml) before nitrogen bombed 
at 450 psi for 5 min. Membranes from disrupted cells were obtained through 
centrifugation (25,000 rpm) at 4 °C for 1 h. Membrane vesicles were formed by passing 
pelleted membranes 20 times through a 27-gauge needle. Membrane vesicles protein 
concentration was determined using Quick Start Bradford Protein Assay (BioRad, 
Hercules, CA). For fluorescence spectroscopic analysis, two reaction mixtures were set 
up: the membrane vesicle protein, 20 µg in Tris sucrose buffer (TSB) (250 mM Tris and 
50 mM sucrose; pH 7.4) and the compound mixture consisting of 10 µM test compounds 
in TSB. The reaction mixtures were separately pre-incubated for 5 min in a 37 °C water 
bath, before they were mixed and incubated afterwards for 10 min to enable ligand 
binding. To stop the reaction, samples were kept on ice prior to analysis with a 
Fluorometer (model FL3-11; HORIBA Edison, New Jersey). Spectroscopic 
measurements were carried out using a 50-uL quartz glass cuvette. The two-color (GFP 
and RFP) P-gp protein was used as an acceptor fluorophore, therefore a previously cloned 
GFP protein was used as the donor fluorophore. Excitation and emission for GFP were 
attained at 465 nm and 480–650 nm respectively. Emission scans were recorded every 3 s 
at 5 nm interval for 10 min.  The intensities of the 2-color P-gp for compound treatments 




efficiency was determined by normalizing  the intensity of the 2-color P-gp acceptor 





where ID and IDA represent the intensities (counts per second, cps) of the donor and 
acceptor fluorophores, respectively. The percent change in FRET was obtained from the 
difference in FRET efficiencies of the ligand-free and the compound-induced treatments.    
 
2.2.10 High content fluorescence inhibition screening data analysis 
 
Analysis of fluorescence inhibition was done using MetaXpress software. The 
software uses segmentation masks to determine the average fluorescent intensities from 
four images captured in each well. Incorporation of segmentation mask subtracts 
background fluorescence. The relative inhibition of calcein-AM efflux by test compounds 
were calculated for each well using the equation below:  
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
𝑋 − 𝑋
𝑋  − 𝑋
 𝑥 100 
where X represents the average fluorescence intensities and T represents the test 
compound. Positive and negative controls were placed in every two columns and used for 
the determination of the percent inhibition for compounds within the same columns. The 
assay quality and validation were assessed using Z’-factor and calculated as follows:   
𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 =  1 −
3(𝜎  + 𝜎 )
|µ  −  µ |
 




2.2.11 Statistical analysis 
 
Statistical analyses were carried out using GraphPad Prism 8.4.3 software 
(GraphPad Software, La Jolla, CA). Analysis of differences between values were 
determined by application of linear mixed model. Dunnett correction was used for 




2.3.1 CIEA compound library screening for P-gp inhibitors 
 
To identify novel P-gp inhibitors, a compound library of 81 CIEAs were screened 
using a high content fluorescence-based transporter activity assay previously developed 
by our group. Screening was performed on P-gp overexpressing cell line, HEK293/P-gp 
using calcein-AM as fluorescent reporter. The positive control inhibitor (reversan 15 µM) 
was considered as baseline (100% inhibition) for calculating the relative percent 
inhibition for the test compounds. As shown in Figure 2.1A, the 2D scatter plot 
represents the relative inhibition activity of each CIEA compound from two independent 
experiments. The cut-off value defined for a positive hit was a compound with ≥50% 
mean percent inhibition. With this cut-off value, 8 CIEA compounds were identified as 
hits. The chemical structures of these compounds are shown in Figure 2.1B. The hit 
compounds and their mean percent inhibition values are shown in Table 2.1. The 
screening assay yielded a correlation value of 0.87 indicating that the two experiments 
had good reproducibility. The assay also yielded an average Z’-factor value of 0.65 























Compound % Calcein Control Inhibition a 
Reversan (Positive inhibitor) 
 
100.00 ± 0.40 
HL 4 
 
78.29 ± 1.94 
HL 15 
 
62.27 ± 13.97 
HL 16 
 
65.35 ± 2.07 
HL 20 
 
50.41 ± 2.92 
HL 21 
 
85.32 ± 2.71 
HL 22 
 
83.27 ± 7.27 
HL 77 
 
59.73 ± 2.45 
HL 80 
 





















Figure 2.1 CIEA compounds screening and selection. (A) Representation of the cell-
based P-gp mediated calcein efflux inhibition screening assay. Screening of a library of 
81 CIEA compounds was conducted in two independent experiments at a compound 
concentration of 10 µM. The 2D plot displays the calculated relative inhibitory activity of 






dots denote compounds with mean percentage inhibition of  ≥ 50%. 2D scatter plot was 
generated using Sigma Plot 12.0 and correlation coefficient was calculated using MS 
Excel. (B) Chemical structures of the 8 CIEA compounds identified hits. 
 
2.3.2 Validation of identified P-gp inhibitors 
 
Based on the results from the high content screening assay, we selected to use two 
well-established cell-based functional assays to confirm the inhibition action of the hit 
compounds and also eliminate false positives. To this end, we evaluated the compounds 
effect on P-gp mediated calcein-AM efflux using flow cytometry. HEK293/pcDNA3.1 
and HEK293/P-gp cells were treated with positive control or test compounds for 10 min 
and with calcein-AM for 30 min. As shown in Figure 2.2A, verapamil at 10 µM 
enhanced calcein accumulation in HEK293/P-gp cells by 10.9 fold compared to the 
untreated cells (control). Moreover, all the hit compounds significantly enhanced calcein 
accumulation in HEK293/P-gp cells at varying degrees (4.0 – 9.6 fold). Compounds HL 
16, HL 21, HL 22 and HL 80 were very potent in inhibiting P-gp, by increasing calcein 
accumulation considerably by 9.2-9.6 fold. On the other hand, no modulatory effect on 
calcein accumulation was observed for the compounds in HEK293/pcDNA3.1 cells.  
Our next direction was to confirm inhibition of P-gp activity by the hit 
compounds on the efflux of another P-gp substrate. The effect of the compounds on P-gp 
mediated doxorubicin (Dox) efflux was observed using confocal microscopy. A two-
color P-gp-GFP-RFP expression vector (GR 678) was transiently transfected into 




transfection provides the means to visualize cells that pick up the vector DNA in the cell 
membrane against non-transfected cells in a single image. After treatment with the 
positive inhibitor or test compounds and incubation with doxorubicin, images acquired 
from the GFP, RFP, and Dox channels were merged and analyzed. P-gp transport of 
doxorubicin was viewed in the nucleus. As shown in Figure 2.2B, the control (DMSO) 
treated cells exhibited high doxorubicin accumulation in the nuclei of non-transfected 
cells, whereas doxorubicin fluorescence was undetectable in cells expressing P-gp-GFP-
RFP. Treatment with positive control, verapamil (10 μM), restored doxorubicin 
accumulation in P-gp-GFP-RFP expressing cells. The compounds HL 15, HL 16, HL 20, 
showed strong doxorubicin accumulation and hence strong inhibition similar to 
verapamil. Moreover, moderate doxorubicin accumulations were observed in cells treated 






















Figure 2.2 Confirmation of inhibitory effect of identified compounds on P-gp activity. 
(A) HEK293/pcDNA3.1 and HEK293/P-gp cells were treated with 0.25 µM calcein-AM 
at 37 °C for 30 min after pretreatment with 10 µM verapamil or test compounds for 10 
min. Collated results from three independent experiments (performed in duplicates) and 






GFP-RFP expression vector (GR 678) was transiently transfected into HEK293T cells. 
After 24-48 h, cells were incubated with 10 µM test compound for 30 min, and then 
treated with doxorubicin (10µM) for 1 h. Images were viewed using confocal microscope 
equipped with a 1.35 numerical aperture 60x oil-immersion objective. GFP and 
Doxorubicin were excited at 488 nm with emission bands at 537/26 nm and 605/64 nm 
respectively. RFP was excited at 561 nm with emission band at 605/64 nm.  
 
2.3.3 Reversal of drug resistance by identified P-gp inhibitors 
 
The CIEA compound library under study in this work were designed to target 
EGFR and MAPK pathways which play significant roles in cancer proliferation and 
differentiation. Nonetheless, we decided to evaluate the capability of these compounds to 
re-sensitize P-gp overexpressing cells to chemotherapeutic agents. Many reports have 
established the ability of P-gp inhibitors to reverse drug resistance as crucial to the 
performance of chemotherapeutic agents in cancers where P-gp is overexpressed. The 
cytotoxic effect of each identified inhibitor compound on HEK293/P-gp cells was first 
determined using a dose-response curve (data not shown). The non-cytotoxic 
concentrations of the compounds were then selected and combined with various 
concentrations of vincristine, paclitaxel or etoposide (common P-gp chemotherapeutic 
substrates) and evaluated for drug resistance reversal. HEK293/pcDNA3.1 was used as 
the negative control cell line. As shown in Figure 2.3A-C, The P-gp overexpressing cell 
line, HEK293/P-gp, (solid red) demonstrated considerable drug resistance as anticipated 




HEK293/pcDNA3.1 (dotted green). Treatment with verapamil reversed resistance of 
HEK293/P-gp (solid blue) towards all three chemotherapeutic drugs. Cell treatments with 
vincristine, paclitaxel and etoposide with their IC50 values and fold resistance are 
represented in Table 2.2. In vincristine treatment, HEK293/P-gp cells showed 290-fold 
greater resistance compared with the control, HEK293/pcDNA3.1. After treatment with 
the known P-gp inhibitor, verapamil (25 µM), the fold resistance of HEK293/P-gp was 
significantly reduced to 0.27-fold. Amongst the 8 hits, compound HL 77 reduced the fold 
resistance of HEK293/P-gp by more than half (111-fold). Compounds HL 4, HL 15, HL 
20 and HL 22 reduced resistance of HEK293/P-gp between 149 and 189-fold while 
compounds HL 16, HL 21 and HL 80 showed modest reduction (between 217 – 256) in 
fold resistance. The CIEA compounds at their non-cytotoxic concentrations reversed the 
resistance of HEK293/P-gp cells towards paclitaxel to various extents. Compounds HL 4, 
HL 16, HL 21, HL 77 and HL 80 reduced the fold resistance of HEK293/P-gp (845-fold)  
to more than half (< 422.5-fold). HL 15, HL 20 and HL 22 demonstrated modest reversal 
of resistance of HEK293/P-gp towards paclitaxel. Treatment of HEK293/P-gp cells with 
etoposide in the absence of inhibitor, produced 173-fold more resistance than the control 
HEK293/pcDNA3.1.In comparison to vincristine and paclitaxel, all the test compounds 
were most effective in sensitizing HEK293/P-gp towards etoposide (reduced resistance 








Table 2.2 Effect of the identified inhibitors on the 1C50 values of vincristine, paclitaxel and etoposide in HEK293/pcDNA3.1 and 
HEK293/P-gp cells. 
 
a  Mean ± SD  of at least three independent experiments performed in triplicates.  
 b Fold resistance determined by dividing the IC50 value for each treatment by the IC50 value of HEK293/pcDNA3.1 treatment with 
vincristine, paclitaxel or etoposide alone. 
Cell line/Treatment IC50a (µM) 
  Vincristine Fold 
resistanceb 




HEK293/pcDNA3.1 0.0038 ± 0.0007 1.00 0.0016 ± 0.0002 1.00 0.0710 ± 0.0574 1.00 
HEK293/P-gp  1.10 ± 0.09 290.16 1.36 ± 0.06 848.57 12.20 ± 1.96 172.68 
HEK293/P-gp + Verapamil [25 µM] 0.0010 ± 0.0005 0.27 0.0031 ± 0.0024 1.92 0.6570 ± 0.0704 9.31 
HEK293/P-gp + HL 4 [2 µM] 0.57 ± 0.13 148.56 0.57 ± 0.13 355.26 2.67 ± 0.57 37.58 
HEK293/P-gp + HL 15 [2 µM] 0.72 ± 0.04 189.03 0.94 ± 0.06 589.89 2.50 ± 0.18 35.34 
HEK293/P-gp + HL 16 [10 µM] 0.97 ± 0.05 255.70 0.39 ± 0.01 241.93 2.65 ± 0.15 37.53 
HEK293/P-gp + HL 20 [2 µM] 0.63 ± 0.22 164.72 0.79 ± 0.12 496.85 2.45 ± 0.19 34.62 
HEK293/P-gp + HL 21 [2 µM] 0.95 ± 0.11 250.71 0.47 ± 0.19 296.79 3.51 ± 0.31 49.64 
HEK293/P-gp + HL 22 [2 µM] 0.68 ± 0.08 178.36 1.14 ± 0.12 712.35 2.38 ± 0.50 33.66 
HEK293/P-gp + HL 77 [2 µM] 0.42 ± 0.09 110.57 0.40 ± 0.07 251.26 3.25 ± 0.71 46.04 















Figure 2.3 Reversal of drug resistance of P-gp overexpressing cells by identified 
compounds towards P-gp anticancer substrates. HEK293/ P-gp cells were treated with 
vincristine (A), paclitaxel (B) and etoposide (C) at increasing concentrations in the 
absence or presence of verapamil (positive inhibitor) and test compounds for 72 h. 
Verapamil concentration was at  25 µM; HL 4, HL 15, HL 20, HL 21, HL 22 and HL 77 
were at 2 µM. HL 16 and  HL 80 concentrations were at 10 µM. HEK293/pcDNA3.1 
cells was used as negative control. Cell viability was evaluated with MTT colorimetric 
assay. Data are representative of three independent experiments and presented as mean ± 







2.3.4 The effect of the identified inhibitors on P-gp protein expression 
 
Since inhibition of ABC transporter-mediated multidrug resistance mechanisms 
may arise from down-regulation at the protein level, we performed western blot to 
determine whether the identified P-gp inhibitors affected the expression of P-gp. As 
shown in Figure 2.4, the expression levels of P-gp (170 kDa) in P-gp overexpressing 
HEK293/P-gp cells were not significantly altered after treatments with 10 µM 
compounds. 
 
Figure 2.4. Expression pattern of P-gp protein in HEK293/P-gp cells treated with 
identified inhibitor compounds. (A) Immunoblots of whole cell lysates prepared from 




loading control. Blots are representative of two independent experiments. (B) Protein 
band densities were quantified using Image Studio Lite (LI-COR Biotechnology, Lincoln, 
NE) software with uneven sample loading and transfer corrected per individual protein 
band relative to α-tubulin. P-gp expression presented as mean ± SEM with  p < 0.05 
compared with control, calculated using linear mixed model and Sidak post hoc test.  
 
2.3.5 Docking of identified P-gp inhibitors with refined mouse P-gp structure 
 
To investigate the binding interaction of the identified inhibitors with P-gp 
protein, a docking grid at the drug binding pocket of the human ABCB1 homology based 
on refined mouse ABCB1 model (PDB code: 4MIM) was created and prepared for 
docking using OpenEye software. The software generates consensus scoring which 
signifies the virtual binding affinity of the ligands to their receptor. A lower consensus 
scoring means good binding affinity of the ligand towards the receptor. From the docking 
studies, all the CIEA compounds displayed better binding affinities (consensus scores: < 
27) towards P-gp than the known P-gp inhibitor, verapamil (consensus score: 27) (Table 
2.3). Compound HL 20 had the lowest consensus score (consensus score:1), representing 
the compound with the strongest binding affinity towards the P-gp binding pocket though 
with no apparent hydrogen bond interaction. Additionally, no hydrogen bond interactions 
were observed for compounds HL 21 and HL 80, though both exhibited equal binding 
affinities (consensus score: 19) toward P-gp. The nitrile group of verapamil hydrogen 
bonded with TYR:306:A at the binding pocket (Figure 2.5A). Hydrogen bond 




hydroxyl substituent groups and specific amino acid residues (Figures 2.5B, 2.6B, 2.8A). 
Both HL 4 and HL 22 interacted with TYR:303:A. GLN:721:A residues which may be 
attributed to the close similarity in their structures. HL 16 interacted with TYR:949:A 
residues at the P-gp binding pocket. The amino phenyl side chain of HL 15 (Figure 2.6A) 
and the hydroxyl group on C-1 of HL 77 (Figure 2.8B) were also involved with hydrogen 
bond interactions with ALA:983:A and ASN:717:A respectively.  
 
Table 2.3 Molecular docking consensus scores, and H-bonding interactions 
for CIEA analogs. Verapamil used as reference drug 
Compound Mol. Wt. Consensus score Target H-bonding residues 
Verapamil 454.602 27 TYR: 306:A 
HL 4  424.572 21 TYR: 303:A; GLN 721: 
HL 15 486.605 16 GLN:986:A 
HL 16 538.63676 11 TYR:949:A  
HL 20 562.70122 1 - 
HL 21 472.57868 19 - 
HL 22 424.57234 18 TYR:303:A; GLN:721:A 
HL 77 502.60466 25 ASN:717:A; 























Figure 2.5 Visual representation for (A) Verapamil and (B) HL 4 within the binding 
pocket of P-gp (PDB ID: 4MIM). Red arrows indicating location of hydrogen bonds 






















Figure 2.6 Visual representation for (A) HL 15 and  (B) HL 16 within the binding pocket 






















Figure 2.7 Visual representation for (A) HL 20 and  (B) HL 21 within the binding pocket 



























Figure 2.8 Visual representation for (A) HL 22 and  (B) HL 77 within the binding pocket 

























Figure 2.9 Visual representation for (A) HL 80 and (B) Overlay of the binding modes of 
all CIEA compounds (gray) and reference compound verapamil (green) within the 






2.3.6 Identified P-gp inhibitors induce dynamic FRET changes 
 
FRET spectroscopy is considered an important biophysical tool for probing 
interactions between cellular molecules at nanoscale distances allowing for accurate 
structural information of molecules. We used the structural-based intramolecular FRET 
approach to investigate our inhibitor compounds interaction with P-gp and also to 
validate the results obtained from the molecular docking studies. The fluorescence 
spectra representation of two-color P-gp in the presence or absence of ligands (test 
compounds) and compound-induced FRET changes are shown in Figures 2.10A and B 
respectively. Compounds HL 4 and HL 15 produced  FRET efficiency changes (~1.5 and 
1.7% respectively) which were close to that of verapamil  (~1.5%). Compound HL 20 
produced the highest increase in FRET efficiency (~15.3%) followed by HL 80 (~9.2%) 
whiles the lowest change in FRET (~0.8%) was observed for HL 16. HL 21, 22 and 77 



























Figure 2.10 Identified inhibitor (CIEA) compounds interaction with P-gp protein. (A) 
Fluorescence spectra representation of two-color P-gp protein (P-gp-GFP-RFP) in the 
absence or presence of ligands (identified P-gp inhibitors). GFP protein was used as 
donor control. (B) Inhibitor compounds-induced FRET changes with two-color P-gp 




with a two-color P-gp, GR 678 were treated with 10 µM of test compounds for 10 min 
before spectroscopic analysis with the fluorometer. Verapamil and JNJ-26854165 were 
included as positive and negative controls, respectively. GFP was excited at 480 nm and 
RFP at 530 nm. Emission for both was achieved at 480-650 nm. Data are representative 





Cancer is the second leading cause of mortality globally accounting for 1 in every 
6 deaths in 2018 [63]. Multidrug resistance mediated by the overexpression of ABC 
transporters is responsible for low patient survival rates in many malignancies. P-gp, the 
most intensively studied MDR-transporter is recognized for its role in MDR due to its 
ability to expel a broad array of drug substrates including anticancer agents out of cells. 
In clinical settings, this function of P-gp serves as a first-line defense mechanism for 
malignant tissues to escape the cytotoxic effects of chemotherapeutic agents. To advance 
patient clinical outcomes in chemotherapy treatments, it is important to overcome P-gp 
mediated MDR through inhibiting its function or down regulating its expression. To date, 
no P-gp inhibitor has gone past the clinical trial stages as a result of unfavorable drug 
effects [48]. Developing and discovering drugs and new compounds that target P-gp 
function is therefore imperative.  
The various types of cucurbitacins and their analogs have shown potential 




and their derivatives on the activity of ABC drug efflux transporters in MDR is less 
studied. Novel compounds known as cucurbitacin-inspired estrone analogs (CIEAs) have 
currently been proven to have antiproliferative activity in hepatocellular carcinoma via 
inhibiting phosphorylation pathways of EGFR and MAPK [66]. In this study, we 
assessed for the first time the potential of the CIEAs to overcome P-gp-mediated MDR in 
vitro. We first employed a high content fluorescence-based transport activity screening 
assay to detect the inhibition of P-gp mediated efflux of calcein-AM, a known P-gp 
substrate by the CIEA compounds. Calcein-AM is a cell permeable, non-fluorescent 
compound that is popularly used in many modulation studies to evaluate the activity of P-
gp [67, 68]. The high content fluorescence-based screening is suitable for screening large 
libraries of natural and synthetic drugs. In addition to being a highly sensitive, in situ 
cell-based technique,  it also incorporates an imaging-based system to directly detect 
cytotoxic effects. The assay identified 8 CIEA compounds as hits for P-gp inhibition with 
good reproducibility (0.87 correlation value) and performance (0.65 Z-factor).  
To validate the results from the high content screening assay, the inhibition 
activity of the hit compounds were further evaluated on P-gp transport activity. All the 
compounds displayed strong inhibition (in comparison to verapamil) of P-gp-mediated 
calcein-AM efflux using flow cytometry. They also demonstrated inhibition of P-gp-
mediated efflux of doxorubicin, in confocal microscopy studies. Furthermore, in drug 
reversal studies, the CIEA compounds demonstrated varying degrees of selectivity 
towards reversal of resistance of the chemotherapeutic drugs vincristine, paclitaxel and 
etoposide in P-gp overexpressing cells. For instance, all the compounds were very 




paclitaxel. Compounds HL 16, HL 21 and HL 80 only showed modest modulatory effect 
in sensitizing  HEK293/P-gp cells towards vincristine while compounds HL15, HL 20 
and HL 22 displayed modest reversal effect in paclitaxel resistance. Based on these 
findings, we think that these CIEA compounds can specifically improve the 
chemotherapeutic response of etoposide in P-gp mediated MDR cancers where P-gp is 
highly expressed.  
To explore the potential mechanisms of inhibition and drug resistance reversal 
effect portrayed by the CIEA compounds, P-gp protein expression studies were 
performed using western blot. The results indicated that the CIEA compounds have no 
effect on P-gp expression at dose (10 µM) that inhibited P-gp efflux suggesting that these 
compounds affect P-gp by mainly inhibiting its efflux function. It has been reported that 
known P-gp inhibitors such as verapamil inhibit P-gp activity by also decreasing its 
expression [69] and this might be useful in treating malignancies where P-gp is 
prominently expressed. However, it is worth noting that the normal physiological defense 
mechanism of P-gp in tissues such as the brain might require typical P-gp expression 
levels and therefore should not be compromised. In this case it will be safe to use 
compounds that only inhibit the transport function of P-gp. 
The molecular basis for the polyspecificity nature of P-gp interaction with 
substrates or inhibitors have been determined by Aller et al.,2009 [9]. In our quest to 
investigate the CIEA compounds interaction with P-gp, molecular docking studies were 
conducted. Our results revealed that all the compounds have better binding affinities 
(based on consensus scoring, Table2.3) towards P-gp at the drug binding pocket than 




and verapamil all docked at similar positions in drug binding pocket. Aller et al 
determined co-crystal structures of P-gp complex with the stereoisomeric cyclic 
hexapeptide inhibitors (QZ59-RRR and QZ59-SSS). They reported that the ligand in 
close proximity to the C-terminal half of the TMD was surrounded by three polar 
residues  GLN-721, GLN-986, and SER-989 [9]. Our compounds HL 4 and HL 22 
interacted through hydrogen bonding with GLN-721 residue, whereas HL 15 hydrogen 
bonded with  GLN-986 at the drug binding pocket of P-gp. In addition, HL16 interacted 
with TYR-949 which was also reported to be in close proximity to TM12. Based on our 
results, we think that inhibition of P-gp transport function by the CIEA compounds may 
be due to strong interaction with C-terminal transmembrane residues at the drug binding 
pocket of P-gp.  
From the docking studies, our attention was then directed to validate the CIEA 
compounds interaction with P-gp protein. Inhibition whether competitive, noncompetitive 
or uncompetitive will require direct binding of the ligand to its target. Using structural-
based fluorescent spectroscopic technique which can measure ligand-induced  
intramolecular FRET changes in the P-gp protein, we showed that all CIEA compounds 
directly interact with P-gp and induced varying degrees of conformational changes. This 
together with our observations from the docking results reinforces our notion that the 
CIEA compounds inhibitory effects on P-gp are due to direct interaction with the 
transporter protein. Nevertheless, further studies are recommended to confirm and map 








 Overall, we have used a high content fluorescence-based transporter activity assay 
to identify cucurbitacin-inspired estrone analogues (CIEA) as potential P-gp inhibitors. 
Validation of their inhibitory activity has also been demonstrated. In addition, these 
compounds were able to reverse drug resistance in P-gp overexpressing cells. Finally, we 
demonstrated that these compounds directly interacted with P-gp protein. This study 
provides vital information on CIEA as sources of new drug discoveries for optimization 
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Novel compounds from cucurbitacin-inspired estrone analogues as inhibitors for 




Multidrug resistance protein 1 (MRP1/ABCC1), a member of the ATP-binding cassette 
(ABC) transporter family, actively transports diverse endogenous and xenobiotic 
substrates including anticancer drugs across membrane barriers. MRP1 is widely 
associated with multidrug resistance in cancer and reportedly responsible for poor patient 
outcome in many hematological malignancies due to its ability to diminish the efficacy of 
a broad range of anticancer agents. In this study, we identified novel inhibitors for MRP1 
by utilizing a high content fluorescence-based transporter activity assay initially 
developed in our lab. From screening a library of 81 novel cucurbitacin-inspired estrone 
analogs (CIEAs) employing doxorubicin and calcein red orange as fluorescent reporters, 
5 compounds were identified as inhibitors of MRP1-mediated doxorubicin efflux and 3 
compounds were identified to inhibit calcein red orange efflux. Out of the 3 compounds 
identified as inhibitors of calcein red orange efflux, 2 (HL 15 and HL 21) were also 
identified as inhibitors from the doxorubicin inhibition assay. Four of the identified CIEA 
compounds were selected for further validation on MRP1 inhibition using well-
established ABC transporter cell-based functional assays. All the selected CIEA 
compounds significantly increased the accumulation of MRP1 substrates, doxorubicin 
and calcein red orange. Drug sensitivity studies also showed selective sensitization of 




vincristine and SN38, however, HL 15 demonstrated good sensitization towards both 
anticancer agents. Moreover, inhibition of MRP1 activity by the CIEA compounds did 
not significantly alter the protein expression levels of MRP1. In silico molecular docking 
and fluorescence spectroscopic studies showed inhibitor compounds directly interacted 
with MRP1 protein suggesting that the CIEA compounds affect the activity of MRP1. In 
summary, the findings in this work provide a novel insight in the utilization of CIEAs as 
promising drug candidates against MRP1-mediated multidrug resistance in cancer.   
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Multidrug resistance protein 1 (MRP 1) is a membrane-associated efflux pump of 
the ATP-binding cassette (ABC) transporter family, an evolutionarily conserved 
superfamily of ATP-dependent transporters that contribute to key cellular processes in all 
organisms. In humans, there are 48 ABC transporter genes divided into seven unique 
subfamilies designated ABCA through ABCG according to their domain organization 
and sequence homology [1]. MRP1 (ABCC1) is the first member of the ‘C’ subfamily, 
known for containing several drug transporters as well as atypical ABC transporters 
including cystic fibrosis transmembrane regulator (CFTR/ABCC7) and sulfonylurea 
receptor (SUR/ABCC8/9) [2-4]. Like several of the ‘C’ subfamily members, the 
structural architecture of the 190 kDa MRP1 protein is characterized by a proximal NH2-
terminal membrane spanning domain (MSD0) in addition to the typical four core 
domains: two MSD (MSD1 and MSD2) and two cytoplasmic nucleotide binding domains 
(NBD1 and NBD2) observed in most ABC proteins [5-8]. The MSD1 and MSD2 contain 
six transmembrane (TM) helices each and form the substrate translocation ‘pore’ through 
which substrates are transported [9]. The transport process is powered by ATP binding 
and hydrolysis at the catalytic core of the 2 NBDs, which is defined by a distinct 
functional asymmetry [10, 11]. The function of the MSD0 although proposed to play a 
role in dimerization still remains poorly understood [12].  
MRP1 is the primary transporter of endogenous anionic substrates such as 
glutathione (GSH), cobalamin, bilirubin, estradiol glucuronide (E217βG) and cysteinyl 




pro-inflammatory molecule, LTC4, makes MRP1 an essential mediator in cellular redox 
homeostasis, cell differentiation, proliferation and immunological reactions. Owing to 
these essential cellular functions, it is not surprising that MRP1is associated with the 
pathophysiology of many metabolic, cardiovascular, neurological, immunological and 
tumor related diseases in humans [16-19].  MRP1 also mediates the efflux of sulfate-
conjugated drugs, or unconjugated drugs concertedly with free glutathione many of 
which include antineoplastic agents like vinca alkaloids, epipodophyllotoxins, 
methotrexate, camptothecins  and many clinically important therapeutics e.g. antibiotics, 
antivirals, antidepressants, statins and metal oxyanions [20, 21].  
In normal tissues, MRP1 is distributed in the lung, gastrointestinal tract, cardiac, 
liver, pancreas, adrenal cortex, skin and skeletal muscle but mainly localized to 
basolateral membranes of polarized epithelia [22]. Importantly, MRP1 is expressed in 
pharmacological sensitive barriers and therefore exerts chemoprotective functions in 
tissues of the brain, testes and placenta [23]. Notwithstanding, MRP1 is the most 
prevalent drug efflux transporter implicated in multidrug resistance (MDR) in cancer 
besides P-gp. Since its discovery in a doxorubicin-selected lung cancer cell line, MRP1 
overexpression in malignant diseases especially hematologic and solid tumors have also 
been confirmed [24-27].  MRP1 confers resistance to tumor cells by actively extruding a 
large number of structurally unrelated chemotherapeutics out of the cells thereby 
affecting the overall drug absorption, disposition and efficacy. The consequence is poor 
clinical outcome in many patients particularly with non-small lung cancer, acute myeloid 
leukemia, (AML), and breast cancer [26, 28, 29]. Clinical investigations have also shown 




resistance traits in tumors [28]. Particularly, various studies on childhood neuroblastoma 
have shown evidence of high MRP1 expression levels as the key individual prognostic 
biomarker of poor patient outcome [30, 31]. Furthermore MRP1, is reported as the target 
of MYCN, the main oncogene frequently amplified in human neuroblastoma [32]. 
Generally, the strategy to overcome ABC transporter-mediated MDR in cancer is 
the pharmacological suppression of drug transporters to restore sensitivity of cancer cells 
to anticancer drugs. A number of inhibitors have been developed and progressed to the 
clinical trial stages for the first drug efflux transporter, P-gp since its discovery over 4 
decades ago [33, 34]. In contrast, the search for MRP1 inhibitors is still at the infancy 
stage and prominent MRP1 inhibitors such as leukotriene D4 (LTD4) receptor antagonist, 
MK571 and ONO-1078 [35, 36]; the anion transport inhibitor, probenecid [37] and the 
nonsteroidal anti-inflammatory drug indomethacin [38, 39] are still currently being 
studied for their activity on MRP1 function. In addition, known P-gp inhibitors such as 
cyclosporine A, PC-883 (valspodor), and verapamil [40] and natural products e.g. 
agosterol and flavonoids [41-44] have all been reported to have inhibitory action on 
MRP1. Most recently, tyrosine kinase inhibitors (TKIs) such as ibrutinib and lapatinib 
have also demonstrated potent MRP1 inhibition [45, 46]. Unfortunately, the action of 
some of these MRP1 inhibitors have been far from satisfactory due to toxicity and severe 
side effects among other reasons [47-49]. The development of more structurally diverse, 
highly potent, less toxic and selective MRP1 inhibitors is thus desirable.   
In our continuous effort to search for novel MRP1 inhibitors, we explored novel 
compound library known as cucurbitacin-inspired estrone analogs (CIEAs) as potential 




oxidized tetracyclic triterpenoids isolated from the plant family Cucurbitaceae. 
Cucurbitacins are well-known for their anticancer, antiproliferative and anti-
inflammatory properties in many types of cancers [50-52]. The CIEAs were designed 
using estrone as starting steroidal scaffold targeting  the EGFR and MAPK pathways 
involved in the proliferation activity of hepatocellular cancer [53]. In the present study, 
we focused on using various in vitro ABC transporter functional evaluation assays and in 
silico molecular docking studies to assess the effects of the CIEA compounds on MRP1 
activity. 
  




Doxorubicin, calcein red orange, poly-D-lysine and thiazolyl blue tetrazolium 
bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO). Vincristine and 
MK571 were procured from Cayman Chemicals (Ann Arbor, MI). SN38 was purchased 
from MedChem Express (Monmouth Junction, NJ). Novel compound library consisting 
of 81 CIEAs were generously provided by Dr. Fathi Halaweish (South Dakota State 
University, Brookings, SD). 
 
3.2.2 Cell lines and cell culture 
 
MRP1 overexpressing cells, H69AR and its parental H69 were  purchased from 
American Type Culture Collection (ATCC) (Manassas, VA) and were cultured in RPMI 




Dakota State University, Brookings, SD) and were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (GE Healthcare, Marlborough, MA). Both media were 
supplemented with 10% (v/v) fetal bovine serum (FBS) (HycloneTM, GE Healthcare Life 
Sciences). All cell lines were maintained at 37 °C in a humidified incubator supplied with 
5% CO2. H69AR cells were challenged with doxorubicin (0.8 μM) once monthly and 
cultured for 7 days drug-free before use.  
3.2.3 Fluorescence-based transporter activity assay via high content screening 
 
 Assay development and optimization were conducted as previously reported [54]. 
The assay was performed on H69AR cells using doxorubicin and calcein red orange as 
fluorescent substrates. Briefly, cells were seeded onto a 96-well optical-bottom plate with 
polymer base (Thermo Fisher Scientific, Waltham, MA) coated with poly-D-lysine 
(Sigma-Aldrich, St. Louis, MO) at a final concentration of 6 x104 per well in 100 μL 
culture medium. After incubation overnight, media was replaced with 80 μL serum free 
media prior to treatment with test compounds and fluorescent substrates. Treatments were 
done using DMSO as negative control at 0.2% final concentration, MK571 as positive 
control at 50 μM final concentration and 10 μM final concentration for test compounds. 
For doxorubicin inhibition screening, cells were initially treated with test compounds or 
positive control for 30 min before incubation with doxorubicin (10 μM final 
concentration) for 2 h. For calcein red orange screening, cells were similarly treated with 
test compound or positive control for 30 min, calcein red orange (0.25 µM final 
concentration) was added and incubated for additional 30 min.  Post incubation with 
fluorescent substrates, cells were rinsed once with PBS and loaded with 100 µL of PBS 




 Fluorescent images were acquired using ImageXpress Micro XLS Widefield High-
Content Analysis System (Molecular Devices, Sunnyvale, CA) equipped with a 0.70 
numerical aperture 60x objective. Four images were acquired from each well in the Texas 
red channel for both fluorescent reporters with excitation and emission at 562/40 nm and 
624/40 nm respectively, and exposure time set for 100 ms. A possible limitation of 
fluorescence experiments in 96-well plates is the gradual decrease in fluorescence across 
the plate due to drop in intracellular fluorescence over time. To account for this, negative 
and positive controls were included in every two columns across the plate. The screening 
assay was conducted in two independent experiments. Fluorescent intensity values from 
images were analyzed using MetaXpress software (version 5.10.41, Molecular Devices). 
The analysis involved segmentation of fluorescent objects in the Texas red channel by a 
custom application model built from the ‘Find Blobs’ module. The model distinguishes 
fluorescent accumulation against a background by applying segmentation masks 
depending on specifications set for object size.  
 
3.2.4 Fluorescence accumulation assay by flow cytometry 
 
Using the same fluorescent substrates (doxorubicin and calcein red orange) 
employed in the high content screening assay, we validated the inhibition activity of the 
identified hit compounds employing flow cytometry. H69 and H69AR cells at a density 
of 7 x105 were suspended in 1 mL serum free media and treated with negative control 
(DMSO at 0.2% v/v) or positive control (MK571 at 50 μM final concentration) or test 
compound (10 μM final concentration). For MRP1-mediated doxorubicin efflux, 




concentration) was added and further incubated for 2 h. MRP1-mediated calcein red 
orange efflux assay involved pretreatment with negative, positive controls and test 
compounds for 10 min at 37 °C before addition of calcein red orange dye (0.25 μM final 
concentration) and further incubation for 30 min. After incubation, the reaction was 
ceased by addition of 3mL ice-cold PBS to each treatment. Cells were pelleted, washed 
twice with ice-cold PBS and then suspended in 1% paraformaldehyde (in ice cold PBS) 
for analysis. Accumulated intracellular fluorescence was determined using BD Accuri C6 
flow cytometer (BD Biosciences, San Jose, CA) equipped with 488 nm argon excitation 
laser. Doxorubicin and calcein red orange were both detected with  > 670 nm band pass 
filter. Two independent experiments were conducted with each sample duplicated. For all 
samples, 10,000 events were collected and mean fluorescent intensities expressed as 
percentage of the control.   
 
3.2.5 Doxorubicin localization assay using confocal microscopy  
 
To further validate the inhibition activity of the identified compounds, we used 
confocal microscopy to qualitatively demonstrate the effect of the compounds on MRP1- 
mediated efflux of an anticancer drug. We elected to use doxorubicin as the common 
anticancer and fluorescent substrate of choice since the compounds identified as 
inhibitors using calcein red orange were also detected with doxorubicin in the high 
content screening. HEK293T cells at a density of  2.5 x 105 cells/well in 2 mL complete 
media were plated into a 6-well plate containing a poly-D-lysine coated (ethanol 
sterilized) cover glass and incubated at 37 °C. At 90 % confluency, cells were transiently 




(Polyplus – transfection SA, Illkirch, France) according to manufacturer’s protocol. After 
48 h, cells were treated with negative control (DMSO at 0.2% v/v) or positive control 
(MK571 50 μM final concentration) or test compound (10 μM final concentration) for 30 
min, and then with doxorubicin (10 µM) for 1 h. Prior to microscopic analysis, cells were 
maintained in a buffer (4.5% glucose, 10mM HEPES and PBS) containing Ca2+ and 
Mg2+.  MRP1 and doxorubicin localization were imaged using an iMIC digital 
microscope (TILL Photonics GmbH, Gräfelfing, Germany) equipped with a 1.35 
numerical aperture 60x oil-immersion objective. Both GFP and doxorubicin were excited 
at 445 nm with emission attained at 537/26 nm and 605/64 nm respectively. Images were 
processed using ImageJ (NIH, Bethesda, MD). 
 
3.2.6 Drug sensitivity studies 
 
The identified MRP1 inhibitors were investigated for their ability to re-sensitize 
multidrug resistant cells to chemotherapeutic drugs using MTT colorimetric assay. H69 
and H69AR cells were plated in a 96-well plate (NEST®, Rahway, NJ) at a concentration 
of 2.5 x 104 cells/well in 100 µL culture medium. The next day, 50 µL of medium 
containing test compounds at non- cytotoxic concentrations were added to cells 1 h prior 
to treatment with 50 µL of the chemotherapeutic drugs (vincristine and SN38) at varying 
concentrations. After incubation for 96 h, 100 µL of culture medium was removed and 
cells were treated with MTT dye (5 mg/ml in PBS) for 4 h. The MTT formazan product 
was dissolved in 100 µL 15% SDS containing 10 mM HCl. Cell viability was determined 
by measuring absorbance at 570 nm with a plate reader, Hidex Sense Beta Plus (Turku, 




3.2.7 Immunoblot analysis 
 
H69 and H69AR cells were seeded in a 6-well plate at 1 x 106  cell density in 2 
mL culture medium per well. After 24 h, cells were treated with or without 10 µM test 
compounds. H69 was used as negative control cell line.  Cell lysis was performed in 
radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher Scientific, Waltham, MA) 
containing 1x Halt Protease Inhibitor Cocktail after 48 h. Lysate protein concentrations 
were determined using Pierce bicinchoninic acid (BCA) Protein Assay. Proteins at 20 µg 
were subjected to electrophoresis on 8.0 % sodium dodecyl sulfate polyacrylamide gels 
before being transferred to PVDF membranes (Immobilon® Millipore, Burlington, MA). 
Membranes were blocked prior to antibody treatments with rabbit monoclonal anti MRP1 
antibody [EPR21062] (1:250; Abcam, ab233383) and anti α-tubulin antibody (1:5000; 
Sigma-Aldrich) and incubated overnight at 4 °C. This was followed by treatment with 
horseradish peroxidase-conjugated goat anti-mouse IgG(H+L) (1:1000; ThermoFisher 
Scientific) secondary antibody for 1 h at room temperature for both MRP1 and α-tubulin. 
MRP1 proteins were developed using Western Blotting Luminol reagent (Santa Cruz 
Biotechnology, sc-2048) and immunoblots visualized with an LI-COR Odyssey Fc 
Imaging System. Resulting protein bands were analyzed with Image Studio Lite version 
5.2 (LI-COR Biotechnology, Lincoln, NE), and the correction for uneven sample loading 
and transfer achieved by applying the relative bands for the loading control (α-tubulin).  






3.2.8 Molecular docking studies 
 
The identified inhibitors were subjected to in silico molecular docking with 
MRP1 protein structure. The structures of the inhibitors (ligands) were prepared for 
docking through energy minimizations using MMFF94 force field application followed 
by ligand conformations utilizing OMEGA application. The binding pocket of the 
receptor, bovine MRP1 (PDB code: 5UJ9) was generated via OpenEye software and 
docking was conducted using FRED (version 2.5.1.4). Docked poses were visualized 
using Vida application (version 4.1.2). 
 
3.2.9 Fluorescence spectroscopic analysis 
 
Membrane vesicles were prepared from HEK293 cells stably transfected with 
GFP- MRP1 (donor control containing only GFP) or a two-color (GFP and RFP) MRP1 
plasmids. Steady-state fluorometry using experimental conditions as previously described 
[55] with slight modifications was performed to determine the intramolecular 
fluorescence resonance energy transfer (FRET) changes of apo (ligand-free) and ligand-
bound MRP1. Briefly, 10 µg MRP1- enriched membrane vesicles in Tris sucrose buffer 
(250 mM Tris and 50 mM sucrose; pH 7.4) initially incubated for 2 min in a 37 °C  water 
bath were treated with 10 µM of test compounds and re- incubated for 10 min. 
Fluorescent spectroscopic measurements were carried out using a 50-uL quartz glass 
cuvette with the Fluorometer model FL3-11 (HORIBA Edison, New Jersey). GFP 
excitation and emission was achieved at 465 nm and 480–650 nm respectively, with 




collected whiles monitoring quenching of the emission peaks from the two-color MRP1 
(acceptor) in the absence or presence of a ligand. Emission scans were collected every 3 s 






where ID and IDA represent the intensities (counts per second, cps) of the donor and 
acceptor fluorophores, respectively. The transfer efficiencies of compound-induced 
samples were normalized with that of the apo condition to obtain the percent change in 
FRET.    
 
3.2.10 High content fluorescence inhibition screening data analysis 
 
Analysis of fluorescence inhibition was performed with MetaXpress software. For 
each well, four images were captured.  Using segmentation masks to subtract background 
fluorescence, the mean fluorescent intensity of each well was determined from the 
average fluorescent values of the four images. The relative efflux inhibition of the 
fluorescent substrates (doxorubicin or calcein red orange) by each test compound was 
determined for each well using the following equation:  
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =
𝑋 − 𝑋  
𝑋 − 𝑋  
 𝑥 100 
with  X representing the average fluorescence intensities of the test compound (T). 




determination of the percent inhibition for compounds within the same column. The 
assay quality and validation were assessed using Z’-factor and calculated as follows:  
𝑍 − 𝑓𝑎𝑐𝑡𝑜𝑟 =  1 −
3(𝜎  + 𝜎  )
|µ  −  µ  |
 
where σ and µ represents standard deviations and means, respectively. 
 
3.2.11 Statistical analysis 
 
Statistical analyses were carried out using GraphPad Prism 8.4.3 software 
(GraphPad Software, La Jolla, CA). Differences between values were analyzed by 
applying linear mixed model and Dunnett correction used for multiple comparisons. 




3.3.1 Fluorescence imaging-based  high-content screening of CIEA library for 
MRP1 inhibitors 
A high content fluorescence inhibition screening assay originally developed in our 
lab was used to screen a library of 81 novel CIEA compounds to identify inhibitors for 
MRP1 using doxorubicin and calcein red orange fluorescent substrates which our lab 
have also established as suitable for identifying inhibitors for MRP1. The 2D scatter plots 
represent the relative percent inhibition by the test compounds on MRP1-mediated efflux 
of doxorubicin and calcein red orange respectively (Figures 3.1A and 3.1B) determined 




performance and reproducibility obtained for doxorubicin and calcein red orange 
inhibition assays were 0.50 and 0.59 respectively. The screening was conducted on 
doxorubicin resistant lung cancer cell line, H69AR. A positive hit was defined as a 
compound with mean percent inhibition of at least 45 % from the two experiments. 
MK571 (50 μM) was used as positive control baseline (100 % inhibition) for determining 
the relative percent inhibition for the test compounds (10 μM). Five compounds were 
identified as inhibitors of MRP1-mediated doxorubicin efflux and three compounds 
identified as calcein red orange efflux inhibitors, including 2 compounds (HL 15 and HL 
21), which were also identified from the doxorubicin inhibition assay (Table 3.1). From 
the hit compounds obtained from both screening assays, four compounds (HL 15, HL 21, 
HL 38 and HL 53) with chemical structures shown in Figure 3.2) were selected for 





























Figure 3.1. Performance of the high content fluorescence-based MRP1-mediated 
doxorubicin and calcein red orange inhibition screening assay. Screening of a library of 
81 CIEA compounds was conducted in two independent experiments at a compound 
Doxorubicin 
A 





concentration of 10 µM using doxorubicin (A) and calcein red orange (B) as fluorescent 
substrates. The 2D plot displays the calculated percentage inhibition of compounds in the 
two experiments. Red and Orange dots denote compounds with mean percentage 
inhibition of  ≥ 45% for doxorubicin and calcein red orange, respectively. 2D scatter plots 
were generated using Sigma Plot 12.0. 
 
Figure 3.2 Chemical structures of 4 selected CIEA compounds identified as hits from 









Table 3.1 Percentage doxorubicin and calcein red orange control inhibition for identified 
MRP1 inhibitors  
Compound % Doxorubicin 
control inhibition a 
% Calcein Red Orange 
control inhibition a 
MK571 100.0 ± 0.0 100.0 ± 0.0 
HL 10 78.3 ± 61.5 
 
HL 15 55.4 ± 14.1 58.0 ± 8.6 
HL 21 45.2 ± 8.9 81.4 ± 16.4 
HL 27 
 
51.2 ± 3.7 
HL 38 81.5 ± 4.7 
 
HL 53 76.8 ± 12.7 
 
 
a  Mean ± SEM of  n = 2 independent experiments   
 
 
3.3.2 Validation of identified CIEA hit compounds 
 
The selected compounds were validated for their inhibition activity on MRP1 
function by employing two well-established ABC transporter functional assays.  First, the 
compounds effect on MRP1 efflux of doxorubicin and calcein red orange were 
determined using flow cytometry. H69 and H69AR cells were incubated with the test 
compounds and the fluorescent substrates at specific time points (as indicated in the 
Materials and Methods section).  As shown in Figure 3.3A, all the identified compounds 
(10 μM) significantly inhibited MRP1-mediated efflux of doxorubicin and thus enhanced 
doxorubicin accumulation in drug resistant H69AR cells but had no significant effect on 
H69, the drug sensitive cell line. The positive control MRP1 inhibitor, MK571 (50 μM) 




was the most effective doxorubicin efflux inhibitor, increasing doxorubicin accumulation 
by ~ 2.0 fold. Modest doxorubicin accumulations (1.3-1.5 fold enhancement) were 
observed for compounds HL 21, HL 38 and HL 53. From the results of the calcein red 
orange accumulation assay (Figure 3.3B), treatment of H69AR cells with HL 15 and HL 
21 also enhanced intracellular calcein red orange levels by ~2.7 fold although MK571 (50 
μM) was seen to increase calcein accumulation significantly by 4.5 fold. The test 
compounds on the other hand, showed only weak modulatory effect in H69 cells. 
In the next validation assay, the effects of the compounds on MRP1-mediated 
efflux of doxorubicin in live cells were qualitatively assessed using confocal microscopy. 
This is because doxorubicin identified more hit compounds amongst which 2 compounds 
were also identified with calcein red orange in the high content screening assay. An 
MRP1-GFP encoding vector was transiently transfected into HEK293T cells. After cells 
were treated with controls or test compounds, localization of doxorubicin in the nucleus 
was visualized. As shown in Figure 3.3C, the nuclei of non-transfected cells in the 
control showed high accumulation of doxorubicin whiles doxorubicin was not detectable 
in MRP1-GFP transfected cells. Treatment with MK571 (50 μM) restored doxorubicin 
localization in MRP1-GFP expressing cells. Compounds HL 15, HL 21, HL 38 and HL 
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Figure 3.3 Validation of identified compounds inhibitory action on  MRP1 efflux 
activity. (A) Doxorubicin accumulation assay. H69 and H69AR cells were pre-treated 
with 50 µM MK571 or test compounds for 2 h before incubation with 10 µM doxorubicin 
at 37 °C for 2 h. Fluorescence intracellular doxorubicin accumulation was measured 
using flow cytometry, with excitation and emission wavelengths of 480 and 670 (LP) nm, 
respectively. (B) Calcein red orange accumulation assay. H69 and H69AR cells were pre-
treated with 50 µM MK571 or test compounds for 10 min before incubation with 25 nM 
calcein red orange at 37 °C for 30 min. Intracellular calcein red orange accumulation was 
quantified using flow cytometry, with excitation and emission wavelengths of 480 and 
585/40 nm, respectively. (C) Doxorubicin localization assay. An MRP1-GFP expression 
vector (green) was transiently transfected into HEK293T cells. After 48 h, cells were 
Control HL 15 MK571 





incubated with 10 µM test compound for 30 min and then with 10µM doxorubicin (red) 
for 1 h. Images were obtained using confocal microscope. GFP and Doxorubicin were 
excited at 488 nm with emission bands of 537/26 nm and 605/64 nm, respectively. 
 
3.3.3 Effects of the identified MRP1 inhibitors (CIEAs) on the efficacy of anticancer 
drugs 
 
MTT colorimetric assay was used to evaluate the ability of the identified MRP1 
inhibitors (CIEA compounds) to reverse resistance of MRP1 overexpressing cancer cells 
(H69AR) to selected anticancer agents. The cytotoxic effect of the test compounds on 
H69AR cells were first analyzed to select compound concentrations that did not 
significantly affect cell viability (data not shown). The non-cytotoxic compound 
concentrations were used in combination with various concentrations of vincristine and 
SN38, prominent MRP1 substrates. Presented in Table 3.2 are the IC50 and fold resistance 
values of the drug resistant cell line, H69AR and its control parental cell line, H69 treated 
with vincristine and SN38 in the presence or absence of test compounds. As expected, 
MRP1 overexpressing H69AR cells showed higher resistance to vincristine (Figure 3.4A, 
red solid line) and SN38 (Figure 3.4B, red solid line) alone compared to H69 (green dash 
line) and produced resistance folds of 12.3 and 206.4 respectively. Addition of positive 
inhibitor, MK571 (10 μM) lowered the resistance folds of H69AR cells to vincristine and 
SN38 from 12.3 to 5.2 fold and 206.4 to 69.5 fold respectively. Compounds HL 15, HL 
21 and HL 38 re-sensitized H69AR cells to vincristine by reducing resistance from 12.3 
fold to the range of 8.2 to 9.6 fold. In contrast, HL 53 did not affect the sensitivity of 




H69AR to SN38 by reducing resistance fold from 206 to 60 -100 fold range. However, 
HL 15 and HL 38 were the most potent sensitizing H69AR to SN38, reducing resistance 




Figure 3.4 Reversal of drug resistance in H69AR cells by the identified MRP1 inhibitors 
towards anticancer substrates. H69 and H69AR cells were treated with vincristine (A) 
and SN38 (B) at increasing drug concentrations in the absence or presence of MK571 and 
test compounds for 72 h . MK571 concentration was at 10 µM; HL 15, HL 38 and HL 53 






using MTT colorimetric assay. Data are representative of at least three independent 
experiments and presented as mean ± SD. 
 
Table 3.2 The effects of identified MRP1 inhibitors on the 1C50 values of vincristine and 
SN38 in H69 and H69AR cells 
 
a  
Mean ± SD of at least three independent experiments performed in triplicates.  
b
 Fold resistance determined by dividing the IC50 value for each treatment by the IC50 
value of    H69 cells treated with vincristine or SN38 alone. 
 
3.3.4 The effects of identified CIEA hits on MRP1 protein expression 
 
We assessed whether the inhibitory action demonstrated by the identified 
compounds had any effect on MRP1 expression at the protein level. Immunoblot analysis 
(Figure 3.5A- B) conducted on MRP1 overexpressing H69AR cells showed that the 
identified CIEA compounds (10 µM) have no significant effect on MRP1 protein 
expression.    
 
 




  SN38                                         Fold
resistanceb 
H69 1.90 ± 0.16 1.00 3.57 ± 1.28 1.00 
H69AR  23.35 ± 5.92 12.30 736.40 ± 61.62 206.41 
H69AR + MK571 [10 9.91 ± 3.11 5.22 247.80 ± 19.85 69.46 
H69AR + HL 15 [2 µM] 16.69 ± 1.99 8.74 216.27 ± 58.12 60.62 
H69AR + HL 21 [0.4 µM] 15.56 ± 3.05 8.20 631.67 ± 139.21 101.37 
H69AR + HL 38 [2 µM] 18.12 ± 1.11 9.55 278.30 ± 78.24 78.01 















Figure 3.5 The effect of CIEA compound inhibitors on MRP1 protein expression. (A) 
Representative immunoblot of whole cell lysates prepared from H69AR cells treated with 
or without 10 µM test compounds for 48 h. (H69 cells were used as negative control). 
MRP1 proteins were detected using goat-anti-rabbit IgG (H+L) (1:1000) and 
confirmation of equal protein loading detected with anti α-tubulin antibody (1:5000). (B) 
Protein band densities were quantified using Image Studio Lite (LI-COR Biotechnology, 
Lincoln, NE) software with uneven sample loading and transfer corrected per individual 















3.3.5 Molecular docking analysis of the identified inhibitors with bovine MRP1 
 
The identified MRP1 inhibitors were docked with bovine MRP1 (91% sequence 
identity with human MRP1 protein) Cryo-EM structure using MK571 as reference 
inhibitor. The best-scored poses of the compounds are represented in Figures 3.6-3.8. The 
hydroxyl group at carbon 17 and the triazole moiety in HL 15 formed hydrogen bond 
interactions with ARG:593:A residues of bovine MRP1 (Figure 3.6B).  In addition, HL 
15 showed equal consensus score (Table 3.3) with MK571 suggesting that both 
compounds may have similar binding affinities towards MRP1. Compound HL 21 
hydrogen bonded with ASN:1244:A residues in MRP1 however with a higher binding 
affinity (consensus score: 8) than MK571. Compounds HL 38 and HL 53, all showed 
lower consensus scores (6) than the reference compound though with no observable 













Table 3.3 Molecular docking consensus scores, molecular weights and H-bonding 
interactions for identified MRP1 inhibitors (CIEA analogs). MK571 used as reference  
drug. 
Compound Mol. Wt. Consensus score Target H-bonding 
residues 
MK571 454.602  10  - 
HL 15 424.572  10 ARG: 593:A 
HL 21 486.605   8 ASN:1244:A 
HL 38 538.637   6 - 































Figure 3.6 Dock poses for (A) MK571 and (B) HL 15 within the binding pocket of 
bovine MRP1 (PDB ID: 5UJ9). Red arrows indicate location of hydrogen bonds (green 





















Figure 3.7 Dock poses for (A) HL 21 and (B) HL 38 within the binding pocket of bovine 
MRP1 (PDB ID: 5UJ9). Red arrows indicate location of hydrogen bonds (green dashed 






















Figure 3.8 Dock poses for (A) HL 53 and (B) Overlay of all compounds along with 






3.3.6 Identified CIEA hits interaction with MRP1 
 
To determine if the identified MRP1 inhibitors directly interact with MRP1 
protein, we employed a novel structural-based approach [56]. This approach makes use of 
two-color recombinant protein engineered from fusing a GFP and RFP with MRP1 
protein structure. The two-color MRP1 protein can potentially detect the direct 
interaction of ligands with MRP1 and determine the intramolecular FRET changes as an 
indicator of conformational changes as a result of ligand binding to MRP1 [57]. Here, 
fluorescence spectroscopic analysis was used to measure the changes in FRET efficiency 
that results upon interaction of the CIEA compounds with the two-color MRP1 protein. 
MK571 was used as positive control and JNJ-26854165, which our group has previously 
reported as showing no interaction with MRP1 [58] was used as the negative control. The 
representative fluorescence spectra of the donor control (containing only GFP) and the 
apo (ligand-free) and ligand-bound (test compound) with two-color MRP1 is shown in 
Figure 3.9A. From the FRET results, (Figure 3.9B), all the identified CIEA compounds 
showed an increase in FRET efficiency relative to the apo condition indicating that they 
directly interact with MRP1. Among the compounds, HL 15 showed the highest FRET 
change (∼7%) while HL 21 induced the smallest change (∼3%).  As expected, MK571 
interacted with MRP1, while JNJ-26854165 yielded no significant FRET change relative 












Figure 3.9 Compound induced intramolecular FRET measurements. (A) Representative 






color MRP1 protein (MRP1-GFP was used as donor control). (B) Compound-dependent 
FRET changes with two-color MRP1 protein. MRP1 membrane vesicles (10 µg) in Tris–
sucrose buffer was prepared and incubated with 10 µM of test compounds for 10 min 
prior to FRET measurements using the fluorometer. GFP and RFP excitations were 
achieved at 465 nm and 530 nm, respectively. Emissions for both GFP and RFP with 
integration time of 3 s were recorded at 480–650 nm. Data are representative of two 
independent experiments performed in triplicates. MK571 and JNJ-26854165 were used 
as positive and negative controls, respectively. Compound induced FRET efficiencies 
were normalized with the apo FRET to obtain the percent change in FRET.  Results are 




Evidence have shown the development of MDR by cancer cells against various 
anticancer agents as the chief obstacle to successful chemotherapy and this has been 
notably linked to overexpressing of ABC drug efflux transporters. Most cancers that 
overexpress MRP1 have poor prognosis and patients have low survival rates due to the 
ability of MRP1 to efflux many first line chemotherapeutic drugs including vincristine, 
doxorubicin and etoposide. For mostly hematological malignancies such as acute 
myeloblastic leukemia and acute lymphoblastic leukemia, MRP1 overexpression has 
been reported as the major determinant limiting the efficacy of chemotherapeutic agents. 
[25, 30, 59]. Furthermore, studies have indicated that genetic variations in MRP1 such as 
common polymorphisms may significantly increase drug resistance and disease 




outcome is a major concern in tumor management in clinical oncology. Clearly, 
inhibition or downregulation of MRP1 is crucial for favorable therapeutic outcomes in 
cancer treatment. Notwithstanding, various small molecular entities targeting MRP1 
activity have been developed with generally organic anion transport inhibitors (e.g. 
probenecid, sulfinpyrazone, indomethacin), tyrosine kinase inhibitors (TKIs) and some P-
gp inhibitors among the leading MRP1 inhibitors. Although various in vitro evaluations 
of these inhibitor compounds and their pharmacokinetic assessments with different 
anticancer agents are still ongoing, motivation for these MRP1 inhibitors to go into 
clinical trials has almost certainly faded due to setbacks (toxicity and zero clinical 
benefits) experienced with P-gp inhibitors [62]. Nonetheless, new drug entities are 
continually being discovered in the hopes of finding the ‘one’ MRP1 inhibitor.   
Presently, there is growing interest in exploiting natural products as new entities 
for drug design due to the less toxic and potent anticancer properties of natural 
derivatives. In the present study, we investigated the ability of the natural product-derived 
cucurbitacin-inspired estrone analogues, CIEAs, as potential MRP1 inhibitors. Firstly, we 
demonstrated inhibition of MRP1 by these analogue compounds using a high content 
fluorescence-based transport activity screening assay already developed and validated in 
our lab. The MRP1 substrates, doxorubicin and calcein red orange were used as 
fluorescent reporters for detection of MRP1 efflux inhibition by the CIEA compounds in 
MRP1-overexpressing H69AR cell line.  Performing two independent screenings on 81 
CIEA compound library, the assay discovered 5 compounds as possible inhibitors of 
MRP1 against doxorubicin efflux and 3 compounds against calcein red orange efflux. 




calcein red orange MRP1-mediated efflux suggesting that these two compounds may 
have common overlapping binding sites for both MRP1 fluorescent substrates. This result 
is also consistent with several biochemical and structural studies demonstrating MRP1’s 
ability to recognize a broad spectrum of substrates as a result of its multiple distinct 
substrate binding sites [63]. The assay yielded average Z’-factors of 0.50 and 0.59 for 
doxorubicin and calcein red orange respectively which prove the fitness and effectiveness 
of the high content screening assay for detecting cell-permeable, non-toxic and potent 
inhibitors in live cells.  
Subsequently, to understand the mechanism of the CIEA compounds on MRP1-
mediated MDR attenuation, and also confirm the high content screening results, we 
performed drug accumulation studies. Our results indeed showed that the compounds 
inhibit MRP1 efflux activity by increasing the intracellular concentrations of doxorubicin 
and calcein red orange in MRP1-overexpressing H69AR cells (Figure 3.3A and 3.3B). 
Visualization of MRP1-mediated efflux of doxorubicin in live cells using confocal 
microscopy also validated the inhibitory action of the CIEAs on MRP1 function.  
The ability of an MRP1 inhibitor to reverse multidrug resistance in cancer cells 
could be very valuable in combinatorial treatment of tumors with especially high MRP1 
expression levels. In the present study, we were interested to know if the CIEA 
compounds were able to reverse MRP1-mediated resistance of common 
chemotherapeutic drugs, vincristine and SN38. However, to prevent the cytotoxic action 
of the CIEA compounds on the reversal outcome, we first obtained a dose-dependent 
response of the CIEA compounds on the selected cell line. We then selected the non-




compounds significantly decreased resistance of H69AR cells towards vincristine. The 
compounds, HL 15, HL 21 and HL 38 reduced the IC50 value of the resistant H69AR 
cells towards vincristine from 23.4 to 16.7, 15.5 and 18.1 nM, respectively. Moreover, 
HL 53 did not show any sensitization of H6AR cells towards vincristine. On the other 
hand, all 4 compounds, HL 15, HL 21, HL 38 and HL 53 reversed resistance of H69AR 
towards SN38 by reducing IC50 value of H69AR resistant cells from 736.4 to 216.2, 
631.7, 278.3 and 357.0 nM respectively. Among the 4 compounds, HL 15 was the most 
potent in reversing resistance of H69AR towards both vincristine and SN38. 
Interestingly, HL 21 was very effective in decreasing resistance of H69AR against 
vincristine but was only modest in sensitizing H69AR cells to SN38. The results suggest 
that substrate selective inhibition of MRP1 by the CIEA compounds may be crucial in 
considering them for combinatorial therapy with chemotherapeutic agents for MDR 
reversal. However, to provide a convincing evidence for the purpose stated, it is 
necessary to investigate their chemosensitization effect in vivo. In addition, it is worth to 
mention that, the reversal studies of these compounds be replicated with different 
chemotherapeutic agents or different MRP1 resistant cell lines to deeply elucidate their 
MDR reversal mechanisms. Further reversal studies could also be performed on other 
ABC transporter MDR cell lines to ascertain whether the CIEA compounds reversal 
capabilities are exclusive to MRP1.  
The circumvention of MDR mediated by ABC transporters may be as a result 
from down-regulation at the protein level. We tested this hypothesis by performing 
Western blotting assay. Our results indicated that, the CIEA compounds have no effect 




inhibition and reversal of MRP1 MDR by the CIEA compounds are independent of 
MRP1 protein down-regulation. This could also mean the possibility of the CIEA 
compounds to inhibit MRP1 activity may be dependent on other protein markers and/or 
cross talk with other cell signaling pathways, which may directly or indirectly affect the 
function of  MRP1. To better elucidate their mechanism of action,  time and 
concentration-dependent studies should be conducted and also various signaling 
pathways probed especially those involved in the EGFR route since this receptor is the 
main pharmacological target of the CIEA compounds.  
To confirm our belief that the CIEA compounds are MRP1 inhibitors and also 
understand their binding interaction with MRP1 protein, we conducted molecular 
docking studies. The results predicted that the CIEA compounds have better binding 
affinities towards MRP1 protein than the known MRP1 inhibitor, MK571. To confirm the 
binding affinities of the CIEA compounds as predicted by the molecular docking studies 
and also investigate the ability of the compounds to directly interact and induced 
conformational changes in MRP1 protein structure, we proceeded to use a two-color 
MRP1 biosensor engineered in our lab coupled with steady-state fluorescence 
spectroscopy. This biosensor has been used to screen a library of 40-novel clinical 
anticancer drugs of which 10 of these drugs possibly interacted with MRP1 as substrates 
[56]. Our FRET-based fluorescence spectroscopy results confirmed that the CIEA 
compounds directly interact with  MRP1 protein which strengthens our conviction that 







3.5 Conclusion   
 
In summary, our study demonstrated the competence of the high content 
screening assay in determining novel inhibitors against MRP1 from a library of 
cucurbitacin inspired estrone analogues (CIEAs). The study was able to investigate CIEA 
compounds as potential MRP1 inhibitors. Functional studies with MRP1 confirmed that 
the CIEA compounds inhibit the function of MRP1 by increasing the accumulation of 
two MRP1 substrates. We also demonstrated the potential of these CIEA compounds to 
re-sensitize MRP1 overexpressing cells to anticancer drugs, which is of great benefit to 
overcome MDR in clinical cancer treatment. Lastly, we also showed that the identified 
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General Conclusions and Recommendations 
In general, we have demonstrated the potential of a novel compound series, CIEA 
as inhibitors for P-gp and MRP1 mediated multidrug resistance. Using a high content 
fluorescence-based transport activity assay, we were able to identify hit compounds 
which were then further validated using established ABC transporter functional assays. 
The hit compounds were also investigated for their reversal effect on multidrug resistant 
cell lines towards selected anticancer agents. Protein expression studies were conducted 
to evaluate the activity of the hit compounds on P-gp and MRP1 protein expression. 
Finally, in silico molecular docking and FRET-based spectroscopic studies were used to 
investigate direct interaction of the hit compounds with P-gp or MRP1 proteins. 
In the first study, the high content fluorescence-based screening identified 8 CIEA 
compounds as positive hits for P-gp inhibition. In addition all the hit compounds 
displayed strong inhibition (in comparison to verapamil) of  P-gp in flow cytometry-
based calcein efflux and confocal microscopy -based doxorubicin localization assays. 
The hit compounds also demonstrated various degrees of reversal of resistance and 
selectivity towards vincristine, paclitaxel and etoposide in P-gp overexpressing multidrug 
resistant HEK293/P-gp cells. However, all the compounds were very effective in 
sensitizing MDR P-gp cells to etoposide. Moreover, protein expression studies revealed 
that the compounds did not alter P-gp expression levels. Thus, the mechanism of P-gp 
inhibition by the CIEA has no suppression on P-gp protein expression. Molecular 
docking studies predicted that all the compounds have better binding affinities towards 




potent in binding to the P-gp domain. Finally, we were able to confirm that the CIEA 
compounds are potential ligands of P-gp. We came to the conclusion that the CIEA 
compounds hold promise for use as agents for inhibiting P-gp mediated multidrug 
resistance.  
In the second study, the high content screening discovered 5 compounds as hits 
for MRP1-mediated doxorubicin efflux inhibition and 3 compounds as inhibitors of 
calcein red orange efflux. Two of the compounds (HL 15 and HL 21) identified as calcein 
red orange inhibitors were also identified to inhibit doxorubicin efflux. The hit 
compounds that were selected for further studies significantly increased the accumulation 
of MRP1 substrates, doxorubicin and calcein red orange in functional characterization 
studies. Drug sensitivity studies also showed selective sensitization of MRP1 
overexpressing H69AR cells by the CIEA compounds towards the anticancer drugs, 
vincristine and SN38,  however, HL 15 demonstrated effective sensitization towards both 
anticancer agents. Similarly as observed in P-gp, the CIEA compounds did not have any 
effect on MRP1 protein expression. In silico molecular docking and fluorescence 
spectroscopic studies confirmed inhibitor compounds interaction with MRP1 protein. 
It is thought that, this study is the first of its kind to report the therapeutic 
potential of CIEA with P-gp and MRP1. We anticipate that the results presented herein 
will provide useful information on cucurbitacin-inspired estrone analogues as sources of 
new drug discoveries for optimization as therapeutic strategies to overcome MDR in 
cancer. 
It is recommended that further studies are conducted to advance the CIEA compounds to 




such as evaluating their effects on ATPase activity which is an important functional 
requirement for P-gp and MRP1 mediated transport. In addition, transport studies using 
membrane vesicles could provide a direct model to understand their mechanism of 
inhibition. Finally, in vitro 3D tumor or vivo models may be used to assess the ultimate 
pharmacokinetic impact of these compounds to establish their efficacy, safety and 
toxicity levels. Depending on their pharmacokinetic profiles, the CIEA compound may 
be optimized to advance their utilization in clinical studies. 
